1. SEATTLE, Sept. 17, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to twenty-five new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on September 17, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 450,000 shares of CTI BioPharma common stock. The options will be issued upon each employee's grant date…

    SEATTLE, Sept. 17, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to twenty-five new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on September 17, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 450,000 shares of CTI BioPharma common stock. The options will be issued upon each employee's grant date (the "Grant Date"), and all stock options included within the equity inducement awards will have an exercise price equal to the closing price of CTI BioPharma common stock on each respective Grant Date. One-fourth of the options will vest on each anniversary of the employee's Grant Date, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301379769.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  2. SEATTLE, Sept. 8, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to seventeen new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on September 8, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 306,000 shares of CTI BioPharma common stock. The options will be issued upon each employee's commencement of…

    SEATTLE, Sept. 8, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to seventeen new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on September 8, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 306,000 shares of CTI BioPharma common stock. The options will be issued upon each employee's commencement of employment (the "Grant Date"), and all stock options included within the equity inducement awards will have an exercise price equal to the closing price of CTI BioPharma common stock on each respective Grant Date. One-fourth of the options will vest on each anniversary of the employee's Grant Date, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor  Contact:

    Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301371987.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  3. SEATTLE, Aug. 26, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to five new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on August 26, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 79,500 shares of CTI BioPharma common stock. The options will be issued upon each employee's grant date (the "Grant…

    SEATTLE, Aug. 26, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to five new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on August 26, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 79,500 shares of CTI BioPharma common stock. The options will be issued upon each employee's grant date (the "Grant Date"), and all stock options included within the equity inducement awards will have an exercise price equal to the closing price of CTI BioPharma common stock on each respective Grant Date. One-fourth of the options will vest on each anniversary of the employee's Grant Date, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301364018.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  4. –  Transaction to Fund Launch and Commercialization of Pacritinib in the United States This Year Pending FDA Approval, and Future Commercialization  –

    SEATTLE and TORONTO, Aug. 25, 2021 /CNW/ - CTI BioPharma Corp. (NASDAQ:CTIC) (CTI) and DRI Healthcare Trust (TSX:DHT) (TSX:DHT) (DRI) today announced transactions totaling up to $135 million in funding for CTI, with $50 million in secured debt to be funded at closing and $60 million to purchase a tiered royalty on sales of pacrinitib upon product approval of pacrinitib by the U.S. Food and Drug Administration (FDA). The proceeds of the transactions will be used by CTI to fund the commercialization of pacritinib for the treatment of myelofibrosis patients with severe thrombocytopenia. CTI has…

    –  Transaction to Fund Launch and Commercialization of Pacritinib in the United States This Year Pending FDA Approval, and Future Commercialization  –

    SEATTLE and TORONTO, Aug. 25, 2021 /CNW/ - CTI BioPharma Corp. (NASDAQ:CTIC) (CTI) and DRI Healthcare Trust (TSX:DHT) (TSX:DHT) (DRI) today announced transactions totaling up to $135 million in funding for CTI, with $50 million in secured debt to be funded at closing and $60 million to purchase a tiered royalty on sales of pacrinitib upon product approval of pacrinitib by the U.S. Food and Drug Administration (FDA). The proceeds of the transactions will be used by CTI to fund the commercialization of pacritinib for the treatment of myelofibrosis patients with severe thrombocytopenia. CTI has a New Drug Application (NDA) under priority review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2021, and is preparing for a potential commercial launch by end of year.

    "CTI is in a strong position to deliver a meaningful new treatment option for patients with myelofibrosis with thrombocytopenia who are in urgent need of new therapies. If we achieve our sales goals in the first two years of launch, we anticipate that this transaction will put us on a clear path to profitability," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI Biopharma. "We thank DRI for their support of CTI and for their partnership during the launch and commercialization of pacritinib."

    "We are excited to announce DRI's partnership with CTI," said Behzad Khosrowshahi, Chief Executive Officer of DRI Healthcare Trust. "Pacritinib is a great addition to our portfolio as a new therapy that addresses a high unmet medical need for patients with myelofibrosis with severe thrombocytopenia."

    "This transaction highlights our ability to offer flexible deal structures that provide DRI with excellent assets and strong cash flow, while providing for the objectives of our partners such as CTI," continued Mr. Khosrowshahi.

    About the Transaction

    DRI Healthcare will provide a $50 million credit facility at closing. The credit facility bears interest at LIBOR + 8.25% (with a LIBOR floor of 1.75%) and is interest-only for the loan term of 5 years, with the outstanding principal due at maturity. The company will be subject to one financial covenant, which is maintaining minimum liquidity of at least $10 million during the term of the loan.

    DRI Healthcare will also provide CTI with $60 million upon receiving accelerated approval of pactritinib, and will receive royalties on annual pacrinitib net sales in the United States of 9.6% for the first $125 million of annual U.S. net sales, 4.5% between $125 million and $175 million of annual U.S. net sales, 0.5% between $175 million and $400 million of annual U.S. net sales, with no entitlement above $400 million of annual U.S. net sales. CTI will be entitled up to an additional $25 million on achievement of certain sales milestones.

    Cowen acted as financial advisor to CTI on this transaction.

    About Myelofibrosis and Severe Thrombocytopenia

    Myelofibrosis is bone marrow cancer that results in formation of fibrous scar tissue and can lead to severe thrombocytopenia and anemia, weakness, fatigue and enlarged spleen and liver. Patients with severe thrombocytopenia are estimated to make up more than one-third of patients treated for myelofibrosis, or approximately 17,000 people in the United States and Europe. Severe thrombocytopenia, defined as blood platelet counts of less than 50,000 per microliter, has been shown to result in overall survival rates of just 15 months. Thrombocytopenia in patients with myelofibrosis is associated with the underlying disease but has also been shown to correlate with treatment with ruxolitinib, which can lead to dose reductions, and as a result, may potentially reduce clinical benefit. Survival in patients who have discontinued ruxolitinib therapy is further compromised, with an average overall survival of seven to 14 months. Myelofibrosis patients with severe thrombocytopenia have limited treatment options, creating a significant area of unmet medical need.

    About Pacritinib

    Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, IRAK1, and CSF1R, but not JAK1. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia, and lymphoma. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and chronic lymphocytic leukemia (CLL), due to its inhibition of c-fms, IRAK1, JAK2 and FLT.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on developing and commercializing pacritinib, our product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis, and in response to the COVID pandemic, severe COVID-19 disease. We are headquartered in Seattle, Washington.

    About DRI Healthcare Trust

    DRI Healthcare Trust provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Our business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties with the aim to deliver attractive growth in cash royalty receipts over the long term. DRI Healthcare Trust is an unincorporated open-ended trust governed by the laws of the Province of Ontario, externally managed by its manager, DRI Capital Inc. DRI Healthcare Trust's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol "DHT.UN" and in U.S. dollars under the symbol "DHT.U".

    CTI BioPharma Forward-Looking Statements

    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to conduct and complete clinical trials in our currently anticipated timeframes; our ability to successfully demonstrate the safety and efficacy of pacritinib; our expectations regarding the completion and outcome of our PACIFICA Phase 3 trial and our PRE-VENT Phase 3 trial; the risk that the FDA may determine that the benefit/risk profile of pacritinib at the dose selected for the PACIFICA Phase 3 trial does not support approval; the risk that the FDA may determine that the benefit/risk profile of pacritinib in the PRE-VENT Phase 3 trial does not support approval or requires additional clinical data for approval; the risk that pacritinib may fail in its development through our PACIFICA and PRE-VENT trials; our ability to receive regulatory approval for pacritinib pursuant to the accelerated approval pathway or at all; the risk that pacritinib may be delayed to a point where it is not commercially viable; the accuracy of our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations; risks relating to our ability to achieve funding milestones under our funding agreement with DRI Capital and loan repayment risks if we do not receive FDA approval of pacritinib within specified timelines; risks and uncertainties related to the COVID-19 pandemic as it relates to our operations and ongoing clinical trials; and those risks more fully discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    DRI Caution Concerning Forward-Looking Statements

    This news release may contain forward-looking information within the meaning of applicable securities legislation. Forward-looking information generally can be identified by the use of forward-looking words such as "expect", "continue", "anticipate", "intend", "aim", "plan", "believe", "budget", "estimate", "forecast", "foresee", "close to", "target" or negative versions thereof and similar expressions. Some of the specific forward-looking information in this news release may include, among other things, statements that CTI has an NDA under priority review by FDA with PDUFA target action data of November 30, 2021, and is preparing for a commercial launch by end of year, and that DRI expects pacrinitib will have a positive impact on those patients whom it treats. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Trust's control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These risks and uncertainties include, but are not limited to, those that are disclosed in the Trust's most recent annual information form and, with respect to pacritinib, those that are disclosed above under "CTI BioPharma Forward-Looking Statements". Certain assumptions underlying the forward-looking information in this news release include: the Trust's assumptions regarding demand and growth in pharmaceutical sales, R&D and opportunities for royalty investing; the competitive environment in which the Trust operates; the performance of the Trust's manager; the Trust's ability to implement its growth strategies; the Trust's ability to obtain financing and maintain its existing financing on acceptable terms; the Trust's ability to maintain good business relationships with marketers and other industry partners; timely receipt of cash royalty receipts; expectations regarding the duration of royalties; the Trust's ability to keep pace with changing consumer preferences; the absence of material adverse changes in the Trust's industry or the global economy; currency exchange and interest rates; the impact of competition; the changes and trends in the Trust's industry or the global economy; and stability in laws, rules, regulations and global standards in the pharmaceutical industry; and, with respect to pacritinib, that regulatory clearance will be obtained on the anticipated timeline and consistent with our expectations, and that the efficacy of pacritinib will be consistent with our expectations. All forward-looking information in this news release speaks as of the date of this news release. The Trust does not undertake to update any such forward-looking information whether as a result of new information, future events or otherwise except as required by law. Additional information about these assumptions and risks and uncertainties is contained in the Trust's filings with securities regulators, including its latest annual information form and Management's Discussion and Analysis. These filings are also available at the Trust's website at dricapital.com.

    SOURCE DRI Healthcare Trust

    Cision View original content: http://www.newswire.ca/en/releases/archive/August2021/25/c6117.html

    View Full Article Hide Full Article
  5. SEATTLE and TORONTO, Aug. 25, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) (CTI) and DRI Healthcare Trust (TSX:DHT) (TSX:DHT) (DRI) today announced transactions totaling up to $135 million in funding for CTI, with $50 million in secured debt to be funded at closing and $60 million to purchase a tiered royalty on sales of pacrinitib upon product approval of pacrinitib by the U.S. Food and Drug Administration (FDA). The proceeds of the transactions will be used by CTI to fund the commercialization of pacritinib for the treatment of myelofibrosis patients with severe thrombocytopenia. CTI has a New Drug Application (NDA) under priority review by FDA with a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2021

    SEATTLE and TORONTO, Aug. 25, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) (CTI) and DRI Healthcare Trust (TSX:DHT) (TSX:DHT) (DRI) today announced transactions totaling up to $135 million in funding for CTI, with $50 million in secured debt to be funded at closing and $60 million to purchase a tiered royalty on sales of pacrinitib upon product approval of pacrinitib by the U.S. Food and Drug Administration (FDA). The proceeds of the transactions will be used by CTI to fund the commercialization of pacritinib for the treatment of myelofibrosis patients with severe thrombocytopenia. CTI has a New Drug Application (NDA) under priority review by FDA with a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2021, and is preparing for a potential commercial launch by end of year.

    "CTI is in a strong position to deliver a meaningful new treatment option for patients with myelofibrosis with thrombocytopenia who are in urgent need of new therapies. If we achieve our sales goals in the first two years of launch, we anticipate that this transaction will put us on a clear path to profitability," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI Biopharma. "We thank DRI for their support of CTI and for their partnership during the launch and commercialization of pacritinib."

    "We are excited to announce DRI's partnership with CTI," said Behzad Khosrowshahi, Chief Executive Officer of DRI Healthcare Trust. "Pacritinib is a great addition to our portfolio as a new therapy that addresses a high unmet medical need for patients with myelofibrosis with severe thrombocytopenia."

    "This transaction highlights our ability to offer flexible deal structures that provide DRI with excellent assets and strong cash flow, while providing for the objectives of our partners such as CTI," continued Mr. Khosrowshahi.

    About the Transaction

    DRI Healthcare will provide a $50 million credit facility at closing. The credit facility bears interest at LIBOR + 8.25% (with a LIBOR floor of 1.75%) and is interest-only for the loan term of 5 years, with the outstanding principal due at maturity. The company will be subject to one financial covenant, which is maintaining minimum liquidity of at least $10 million during the term of the loan.

    DRI Healthcare will also provide CTI with $60 million upon receiving accelerated approval of pactritinib, and will receive royalties on annual pacrinitib net sales in the United States of 9.6% for the first $125 million of annual U.S. net sales, 4.5% between $125 million and $175 million of annual U.S. net sales, 0.5 % between $175 million and $400 million of annual U.S. net sales, with no entitlement above $400 million of annual U.S. net sales. CTI will be entitled up to an additional $25 million on achievement of certain sales milestones.

    Cowen acted as financial advisor to CTI on this transaction.

    About Myelofibrosis and Severe Thrombocytopenia

    Myelofibrosis is bone marrow cancer that results in formation of fibrous scar tissue and can lead to severe thrombocytopenia and anemia, weakness, fatigue and enlarged spleen and liver. Patients with severe thrombocytopenia are estimated to make up more than one-third of patients treated for myelofibrosis, or approximately 17,000 people in the United States and Europe. Severe thrombocytopenia, defined as blood platelet counts of less than 50,000 per microliter, has been shown to result in overall survival rates of just 15 months. Thrombocytopenia in patients with myelofibrosis is associated with the underlying disease but has also been shown to correlate with treatment with ruxolitinib, which can lead to dose reductions, and as a result, may potentially reduce clinical benefit. Survival in patients who have discontinued ruxolitinib therapy is further compromised, with an average overall survival of seven to 14 months. Myelofibrosis patients with severe thrombocytopenia have limited treatment options, creating a significant area of unmet medical need.

    About Pacritinib

    Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, IRAK1, and CSF1R, but not JAK1. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia, and lymphoma. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and chronic lymphocytic leukemia (CLL), due to its inhibition of c-fms, IRAK1, JAK2 and FLT.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on developing and commercializing pacritinib, our product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis, and in response to the COVID pandemic, severe COVID-19 disease. We are headquartered in Seattle, Washington.

    About DRI Healthcare Trust

    DRI Healthcare Trust provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Our business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties with the aim to deliver attractive growth in cash royalty receipts over the long term. DRI Healthcare Trust is an unincorporated open-ended trust governed by the laws of the Province of Ontario, externally managed by its manager, DRI Capital Inc. DRI Healthcare Trust's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol "DHT.UN" and in U.S. dollars under the symbol "DHT.U".

    CTI BioPharma Forward-Looking Statements

    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to conduct and complete clinical trials in our currently anticipated timeframes; our ability to successfully demonstrate the safety and efficacy of pacritinib; our expectations regarding the completion and outcome of our PACIFICA Phase 3 trial and our PRE-VENT Phase 3 trial; the risk that the FDA may determine that the benefit/risk profile of pacritinib at the dose selected for the PACIFICA Phase 3 trial does not support approval; the risk that the FDA may determine that the benefit/risk profile of pacritinib in the PRE-VENT Phase 3 trial does not support approval or requires additional clinical data for approval; the risk that pacritinib may fail in its development through our PACIFICA and PRE-VENT trials; our ability to receive regulatory approval for pacritinib pursuant to the accelerated approval pathway or at all; the risk that pacritinib may be delayed to a point where it is not commercially viable; the accuracy of our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations; risks relating to our ability to achieve funding milestones under our funding agreement with DRI Capital and loan repayment risks if we do not receive FDA approval of pacritinib within specified timelines; risks and uncertainties related to the COVID-19 pandemic as it relates to our operations and ongoing clinical trials; and those risks more fully discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    DRI Caution Concerning Forward-Looking Statements

    This news release may contain forward-looking information within the meaning of applicable securities legislation. Forward-looking information generally can be identified by the use of forward-looking words such as "expect", "continue", "anticipate", "intend", "aim", "plan", "believe", "budget", "estimate", "forecast", "foresee", "close to", "target" or negative versions thereof and similar expressions. Some of the specific forward-looking information in this news release may include, among other things, statements that CTI has an NDA under priority review by FDA with PDUFA target action data of November 30, 2021, and is preparing for a commercial launch by end of year, and that DRI expects pacrinitib will have a positive impact on those patients whom it treats. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Trust's control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These risks and uncertainties include, but are not limited to, those that are disclosed in the Trust's most recent annual information form and, with respect to pacritinib, those that are disclosed above under "CTI BioPharma Forward-Looking Statements". Certain assumptions underlying the forward-looking information in this news release include: the Trust's assumptions regarding demand and growth in pharmaceutical sales, R&D and opportunities for royalty investing; the competitive environment in which the Trust operates; the performance of the Trust's manager; the Trust's ability to implement its growth strategies; the Trust's ability to obtain financing and maintain its existing financing on acceptable terms; the Trust's ability to maintain good business relationships with marketers and other industry partners; timely receipt of cash royalty receipts; expectations regarding the duration of royalties; the Trust's ability to keep pace with changing consumer preferences; the absence of material adverse changes in the Trust's industry or the global economy; currency exchange and interest rates; the impact of competition; the changes and trends in the Trust's industry or the global economy; and stability in laws, rules, regulations and global standards in the pharmaceutical industry; and, with respect to pacritinib, that regulatory clearance will be obtained on the anticipated timeline and consistent with our expectations, and that the efficacy of pacritinib will be consistent with our expectations. All forward-looking information in this news release speaks as of the date of this news release. The Trust does not undertake to update any such forward-looking information whether as a result of new information, future events or otherwise except as required by law. Additional information about these assumptions and risks and uncertainties is contained in the Trust's filings with securities regulators, including its latest annual information form and Management's Discussion and Analysis. These filings are also available at the Trust's website at dricapital.com.

    CTI BioPharma Investor Contacts:

    David Kirske                          

    Argot Partners

    Chief Financial Officer            

    +212-600-1902

    CTI BioPharma Corp.              

    cti@argotpartners.com

    +206-272-4004



     

    DRI Healthcare Trust Investor Contacts:

    Stewart Busbridge

    Rhizza Marbella

    Chief Operating Officer

    VP, Corporate Accounting & Investor Relations

    DRI Capital Inc.

    DRI Capital Inc.

    +416-726-0140

    +416-324-5738



    ir@drihealthcare.com 

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-and-dri-healthcare-trust-announce-up-to-135-million-debt-and-royalty-transaction-301362310.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  6. SEATTLE, Aug. 24, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks has overseen the launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Amgen, and Genentech.

    "Diane is an accomplished leader with considerable experience driving the successful planning, launch, and commercialization of new medicines in hematology and oncology," said Laurent Fischer, M.D., Chairman of the Board of CTI Biopharma. "We are pleased to have Diane join CTI's Board of Directors at this pivotal time as we advance our JAK2/IRAK-1 inhibitor pacritinib towards a potential U.S. approval for the treatment of patients…

    SEATTLE, Aug. 24, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks has overseen the launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Amgen, and Genentech.

    "Diane is an accomplished leader with considerable experience driving the successful planning, launch, and commercialization of new medicines in hematology and oncology," said Laurent Fischer, M.D., Chairman of the Board of CTI Biopharma. "We are pleased to have Diane join CTI's Board of Directors at this pivotal time as we advance our JAK2/IRAK-1 inhibitor pacritinib towards a potential U.S. approval for the treatment of patients with myelofibrosis later this year."

    "I am excited to collaborate with CTI's Board of Directors and management team as they continue to execute on commercial preparation activities to potentially launch pacritinib this year," said Ms. Parks. "I share CTI's dedication to delivering new treatment options for patients with blood cancers who are underserved by existing therapies, and I look forward to contributing strategic counsel that draws upon my extensive commercial hematology and oncology experiences."

    Throughout Ms. Parks' biopharma industry career spanning more than three decades, she has held a variety of commercial leadership positions. As Senior Vice President, Head of U.S. Commercial at Kite Pharma (acquired by Gilead for $11.9 billion), Ms. Parks led the launch and "go to market" strategic planning and execution for YESCARTA®, the first CAR-T therapy for relapsed or refractory large B-cell lymphoma. As Vice President, Head of Global Marketing at Pharmacyclics (acquired by AbbVie for $21 billion), she oversaw the development and execution of all marketing strategies, as well as data insights to inform commercial decision making, for IMBRUVICA® for the treatment of Waldenstrom's macroglobulinemia and chronic lymphocytic leukemia. At Amgen, she led the nephrology and hospital sales teams and launched three products, including for colorectal cancer and idiopathic thrombocytopenia, in the academic hospital market. In a variety of roles at Genentech (acquired by Roche for $46.8 billion), including Senior Vice President, Specialty Biotherapeutics and Managed Care, she led sales, marketing, and other commercial operations activities and launched multiple products. Currently, Ms. Parks serves on the Board of Directors of Calliditas Therapeutics AB, Soligenix, TriSalus Life Sciences, Kura Oncology, and the Lymphoma Research Foundation. She holds a B.S. from Kansas State University and an M.B.A. from Georgia State University.

    About Myelofibrosis and Severe Thrombocytopenia

    Myelofibrosis is bone marrow cancer that results in formation of fibrous scar tissue and can lead to severe thrombocytopenia and anemia, weakness, fatigue and enlarged spleen and liver. Patients with severe thrombocytopenia are estimated to make up more than one-third of patients treated for myelofibrosis, or approximately 17,000 people in the United States and Europe. Severe thrombocytopenia, defined as blood platelet counts of less than 50,000 per microliter, has been shown to result in overall survival rates of just 15 months. Thrombocytopenia in patients with myelofibrosis is associated with the underlying disease but has also been shown to correlate with treatment with ruxolitinib, which can lead to dose reductions, and as a result, may potentially reduce clinical benefit. Survival in patients who have discontinued ruxolitinib therapy is further compromised, with an average overall survival of seven to 14 months. Myelofibrosis patients with severe thrombocytopenia have limited treatment options, creating a significant area of unmet medical need.

    About Pacritinib

    Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, IRAK1, and CSF1R, but not JAK1. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia, and lymphoma. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and chronic lymphocytic leukemia (CLL), due to its inhibition of c-fms, IRAK1, JAK2 and FLT.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on developing and commercializing pacritinib, our product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis, and in response to the COVID pandemic, severe COVID-19 disease. We are headquartered in Seattle, Washington.

    CTI BioPharma Forward-Looking Statements

    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to conduct and complete clinical trials in our currently anticipated timeframes; our ability to successfully demonstrate the safety and efficacy of pacritinib; our expectations regarding the completion and outcome of our PACIFICA Phase 3 trial and our PRE-VENT Phase 3 trial; the risk that the FDA may determine that the benefit/risk profile of pacritinib at the dose selected for the PACIFICA Phase 3 trial does not support approval; the risk that the FDA may determine that the benefit/risk profile of pacritinib in the PRE-VENT Phase 3 trial does not support approval or requires additional clinical data for approval; the risk that pacritinib may fail in its development through our PACIFICA and PRE-VENT trials; our ability to receive regulatory approval for pacritinib pursuant to the accelerated approval pathway or at all; the risk that pacritinib may be delayed to a point where it is not commercially viable; the accuracy of our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations; risks and uncertainties related to the COVID-19 pandemic as it relates to our operations and ongoing clinical trials; and those risks more fully discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:

    Argot Partners

    +212-600-1902

    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-announces-appointment-of-diane-parks-to-its-board-of-directors-301361235.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  7. SEATTLE, Aug. 5, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the second quarter ended June 30, 2021.

    "This past quarter, we continued to advance pacritinib towards a potential U.S. approval and commercial launch this year. The U.S. Food and Drug Administration's acceptance with priority review of our NDA submission for the use of pacritinib in myelofibrosis patients with severe thrombocytopenia underscores the unmet need in this area," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI Biopharma. "With a PDUFA target action date of November 30, 2021, and commercial preparations already well underway, we will be well positioned for a potential U.S. launch…

    SEATTLE, Aug. 5, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the second quarter ended June 30, 2021.

    "This past quarter, we continued to advance pacritinib towards a potential U.S. approval and commercial launch this year. The U.S. Food and Drug Administration's acceptance with priority review of our NDA submission for the use of pacritinib in myelofibrosis patients with severe thrombocytopenia underscores the unmet need in this area," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI Biopharma. "With a PDUFA target action date of November 30, 2021, and commercial preparations already well underway, we will be well positioned for a potential U.S. launch later this year. We are working closely with the FDA during the review of our application and we continue to advance our commercial launch activities."

    Expected Milestones

    • PDUFA action date – November 30, 2021
    • Expected U.S. commercial launch of pacritinib – by the end of 2021
    • Reporting of interim analysis from the Phase 3 PRE-VENT trial in hospitalized patients with severe COVID-19 – Q3 2021

    Second Quarter Financial Results

    Operating loss was $19.5 million and $36.6 million for the three and six months ended June 30, 2021, respectively, compared to operating loss of $10.0 million and $21.9 million for the corresponding periods in 2020. The increase in operating loss for the three and six months ended June 30, 2021 as compared to the comparable periods in 2020 resulted primarily from increases in research and development and general and administrative activities associated with continued development and preparation for the potential commercialization of pacritinib.

    Net loss for the three months ended June 30, 2021 was $19.7 million, or $0.21 for basic and diluted loss per share, compared to net loss of $14.0 million, or $0.19 for basic and diluted loss per share, for the same period in 2020. Net loss for the six months ended June 30, 2021 was $36.9 million, or $0.44 for basic and diluted loss per share, compared to net loss of $26.2 million, or $0.38 for basic and diluted loss per share, for the same period in 2020.

    As of June 30, 2021, cash, cash equivalents and short-term investments totaled $71.9 million, as compared to $52.5 million as of December 31, 2020. We expect our current cash and cash equivalents will enable us to fund our operations into the fourth quarter of 2021.

    Conference Call and Webcast

    CTI will host a conference call and webcast to review its second quarter 2021 financial results and provide an update on business activities today, August 5 at 4:30 PM ET. To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 6891246. A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com. A replay of the webcast will be available for 30 days following the event.

    About Myelofibrosis and Severe Thrombocytopenia

    Myelofibrosis is bone marrow cancer that results in formation of fibrous scar tissue and can lead to severe thrombocytopenia and anemia, weakness, fatigue and enlarged spleen and liver. Patients with severe thrombocytopenia are estimated to make up more than one-third of patients treated for myelofibrosis, or approximately 17,000 people in the United States and Europe. Severe thrombocytopenia, defined as blood platelet counts of less than 50,000 per microliter, has been shown to result in overall survival rates of just 15 months. Thrombocytopenia in patients with myelofibrosis is associated with the underlying disease but has also been shown to correlate with treatment with ruxolitinib, which can lead to dose reductions, and as a result, may potentially reduce clinical benefit. Survival in patients who have discontinued ruxolitinib therapy is further compromised, with an average overall survival of seven to 14 months. Myelofibrosis patients with severe thrombocytopenia have limited treatment options, creating a significant area of unmet medical need.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis, and in response to the COVID pandemic, severe COVID-19 disease. We are headquartered in Seattle, Washington.

    Forward-Looking Statements

    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to conduct and complete clinical trials in our currently anticipated timeframes; our ability to successfully demonstrate the safety and efficacy of pacritinib; our expectations regarding the completion and outcome of our PACIFICA Phase 3 trial and our PRE-VENT Phase 3 trial; the risk that the FDA may determine that the benefit/risk profile of pacritinib at the dose selected for the PACIFICA Phase 3 trial does not support approval; the risk that the FDA may determine that the benefit/risk profile of pacritinib in the PRE-VENT Phase 3 trial does not support approval or requires additional clinical data for approval; the risk that pacritinib may fail in its development through our PACIFICA and PRE-VENT trials; our ability to receive regulatory approval for pacritinib pursuant to the accelerated approval pathway or at all; the risk that pacritinib may be delayed to a point where it is not commercially viable; the accuracy of our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations; risks and uncertainties related to the COVID-19 pandemic as it relates to our operations and ongoing clinical trials; and those risks more fully discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:

    Argot Partners

    +212-600-1902

    cti@argotpartners.com

    (tables follow)

     

    CTI BioPharma Corp.

    Condensed Consolidated Statements of Operations

    (In thousands, except per share amounts)

    (unaudited)





    Three Months Ended

     June 30,



    Six Months Ended

    June 30,



    2021



    2020



    2021



    2020

    Operating costs and expenses:















    Research and development

    $

    9,293





    $

    6,199





    $

    18,737





    $

    9,463



    General and administrative

    10,213





    3,797





    17,839





    8,264



    Other operating expenses













    4,200



    Total operating costs and expenses

    19,506





    9,996





    36,576





    21,927



    Loss from operations

    (19,506)





    (9,996)





    (36,576)





    (21,927)



    Non-operating income (expense):















    Interest income

    8





    43





    19





    162



    Interest expense

    (45)





    (137)





    (113)





    (304)



    Amortization of debt discount and issuance costs

    (130)





    (130)





    (260)





    (260)



    Foreign exchange loss

    (2)





    (6)





    (11)





    (83)



    Loss on dissolution of majority-owned subsidiary





    (3,774)









    (3,774)



    Total non-operating expense, net

    (169)





    (4,004)





    (365)





    (4,259)



    Net loss

    $

    (19,675)





    $

    (14,000)





    $

    (36,941)





    $

    (26,186)



    Basic and diluted net loss per common share

    $

    (0.21)





    $

    (0.19)





    $

    (0.44)





    $

    (0.38)



    Shares used in calculation of basic and diluted net loss per common share:

    92,341





    73,685





    84,398





    68,073



     

    Balance Sheet Data (unaudited):



    (amounts in thousands)





    June 30,



    December 31,





    2021



    2020

    Cash and cash equivalents



    $

    71,881





    $

    40,394



    Short-term investments







    12,057



    Working capital



    59,030





    37,287



    Total assets



    77,495





    58,241



    Current portion of long-term debt



    2,049





    4,455



    Total stockholders' equity



    61,706





    40,029



     

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-reports-second-quarter-2021-financial-results-301349723.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  8. SEATTLE, July 29, 2021 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ:CTIC) today announced that management plans to report its second quarter 2021 financial results on Thursday, August 5, 2021, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT).

    To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 6891246. A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com. A replay of the webcast will be available…

    SEATTLE, July 29, 2021 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ:CTIC) today announced that management plans to report its second quarter 2021 financial results on Thursday, August 5, 2021, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT).

    To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 6891246. A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com. A replay of the webcast will be available for 30 days following the event.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Argot Partners

    +212-600-1902

    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-report-second-quarter-2021-financial-results-on-august-5-2021-301344010.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  9. SEATTLE, July 26, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on July 23, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 68,000 shares of CTI BioPharma common stock. The options will be issued upon each employee's commencement of employment…

    SEATTLE, July 26, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on July 23, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 68,000 shares of CTI BioPharma common stock. The options will be issued upon each employee's commencement of employment (the "Grant Date"), and all stock options included within the equity inducement awards will have an exercise price equal to the closing price of CTI BioPharma common stock on each respective Grant Date. One-fourth of the options will vest on each anniversary of the employee's Grant Date, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301341364.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  10. SEATTLE, July 8, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employee's acceptance of employment with the company. The equity award was approved on July 8, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employee received options to purchase 12,000 shares of CTI BioPharma common stock. The options will be issued upon the employee's grant date (the "Grant Date"), and all stock options…

    SEATTLE, July 8, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employee's acceptance of employment with the company. The equity award was approved on July 8, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employee received options to purchase 12,000 shares of CTI BioPharma common stock. The options will be issued upon the employee's grant date (the "Grant Date"), and all stock options included within the equity inducement award will have an exercise price equal to the closing price of CTI BioPharma common stock on the Grant Date. One-fourth of the options will vest on each anniversary of the employee's Grant Date, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com 

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301328506.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  11. SEATTLE, June 23, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on June 23, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 25,500 shares of CTI BioPharma common stock. The options will be issued upon each employee's grant date (the "Grant Date"), and all stock options included within the equity inducement awards will have an exercise price equal to the closing price of CTI BioPharma common stock on each respective Grant Date. One-fourth of the options will vest on each anniversary of the employee's Grant Date, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301318734.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  12. SEATTLE, June 9, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on June 8, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 47,500 shares of CTI BioPharma common stock. The options will be issued upon each employee's commencement of employment (the "Grant Date"), and all stock…

    SEATTLE, June 9, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on June 8, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 47,500 shares of CTI BioPharma common stock. The options will be issued upon each employee's commencement of employment (the "Grant Date"), and all stock options included within the equity inducement awards will have an exercise price equal to the closing price of CTI BioPharma common stock on each respective Grant Date. One-fourth of the options will vest on each anniversary of the employee's Grant Date, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301309539.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  13. SEATTLE, June 9, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that management will provide a corporate overview at the JMP Securities Life Sciences Conference at 2:30 p.m. ET. The conference will be held in a virtual meeting format.

    Presentation details:

    Event: JMP Securities Life Sciences Conference

    Date: Wednesday, June 16, 2021

    Time: 2:30 p.m. ET

    The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis, and in response to the COVID pandemic, severe COVID-19 disease. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Argot Partners

    +212-600-1902

    cti@argotpartners.com

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-jmp-securities-life-sciences-conference-on-wednesday-june-16-301308699.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  14. SEATTLE, June 1, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the first quarter ended March 31, 2021.

    "The U.S. Food and Drug Administration's (FDA) acceptance of our New Drug Application (NDA) for pacritinib with priority review and a Prescription Drug User Fee Act (PDUFA) action date of November 30, 2021 brings us one step closer to providing pacritinib to myelofibrosis patients with severe thrombocytopenia who are underserved by existing therapies," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI Biopharma. "We continue to work diligently on our commercial preparedness and expect to be ready to launch pacritinib in the United States this year, pending approval…

    SEATTLE, June 1, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the first quarter ended March 31, 2021.

    "The U.S. Food and Drug Administration's (FDA) acceptance of our New Drug Application (NDA) for pacritinib with priority review and a Prescription Drug User Fee Act (PDUFA) action date of November 30, 2021 brings us one step closer to providing pacritinib to myelofibrosis patients with severe thrombocytopenia who are underserved by existing therapies," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI Biopharma. "We continue to work diligently on our commercial preparedness and expect to be ready to launch pacritinib in the United States this year, pending approval by the FDA. To that end, over the last quarter, we progressed key pre-commercial activities to prepare for a successful and rapid launch upon approval, including market access, distribution and supply chain, disease education and field force planning and deployment. We look forward to continuing these efforts, and to work closely with the FDA during its review of our application."

    Expected Milestones

    • PDUFA action date – November 30, 2021
    • Expected U.S. commercial launch of pacritinib – by the end of 2021
    • Reporting of interim analysis from the Phase 3 PRE-VENT trial in hospitalized patients with severe COVID-19 – Q3 2021

    First Quarter Financial Results

    Operating loss was $17.1 million and $11.9 million for the three months ended March 31, 2021 and 2020, respectively. The increase in operating loss resulted primarily from increases in research and development and general and administrative activities associated with continued development and preparation for the commercialization of pacritinib.

    Net loss for the three months ended March 31, 2021 was $17.3 million, or $0.23 for basic and diluted loss per share, as compared to a net loss of $12.2 million, or $0.20 for basic and diluted loss per share, for the same period in 2020.

    As of March 31, 2021, cash, cash equivalents and short-term investments totaled $37.2 million, as compared to $52.5 million as of December 31, 2020.  On April 6, 2021 we completed an equity financing with net proceeds of $53.8 million, which enables us to fund our operations into the fourth quarter of 2021.

    Conference Call and Webcast

    CTI will host a conference call and webcast to review its first quarter 2021 financial results and provide an update on business activities today, June 1 at 4:30 PM ET. To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 9343326. A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com. A replay of the webcast will be available for 30 days following the event.

    About Myelofibrosis and Severe Thrombocytopenia

    Myelofibrosis is a type of bone marrow cancer that results in formation of fibrous scar tissue and can lead to severe thrombocytopenia and anemia, weakness, fatigue and enlarged spleen and liver. Patients with severe thrombocytopenia are estimated to make up one-third of patients treated for myelofibrosis, or approximately 17,000 people in the United States and Europe. Severe thrombocytopenia, defined as blood platelet counts of less than 50 x 109/L, has been shown to result in overall survival rates of just 15 months. Thrombocytopenia in patients with myelofibrosis is associated with the underlying disease but has also been shown to result from treatment with ruxolitinib, which can lead to dose reductions, and as a result, may potentially reduce clinical benefit. Survival in patients who have discontinued ruxolitinib therapy is further compromised, with an average overall survival of seven to 14 months. Myelofibrosis patients with severe thrombocytopenia have limited treatment options, and represent an area of significant area of unmet medical need.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis, and in response to the COVID pandemic, severe COVID-19 disease. We are headquartered in Seattle, Washington.

    Forward-Looking Statements

    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to successfully demonstrate the safety and efficacy of, and receive regulatory approval for, pacritinib; the risk that the FDA may determine that the benefit/risk profile of pacritinib at the dose selected for the PACIFICA Phase 3 trial does not support approval; our expectations regarding the completion and outcome of our PRE-VENT Phase 3 trial; the risk that pacritinib may be delayed to a point where it is not commercially viable; the accuracy of our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations; risks and uncertainties related to the COVID-19 pandemic as it relates to our operations and ongoing clinical trials; and those risks more fully discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:

    Argot Partners

    +212-600-1902

    cti@argotpartners.com

    (tables follow)

    CTI BioPharma Corp.

    Condensed Consolidated Statements of Operations

    (In thousands, except per share amounts)

    (unaudited)



    Three Months Ended

     March 31,



    2021



    2020

    Operating costs and expenses:







    Research and development

    $

    9,444



    $

    3,264

    General and administrative

    7,626



    4,467

    Other operating expenses



    4,200

    Total operating costs and expenses

    17,070



    11,931

    Loss from operations

    (17,070)



    (11,931)

    Non-operating income (expense):







    Interest income

    11



    119

    Interest expense

    (68)



    (167)

    Amortization of debt discount and issuance costs

    (130)



    (130)

    Foreign exchange loss

    (9)



    (77)

    Total non-operating expense, net

    (196)



    (255)

    Net loss

    $

    (17,266)



    $

    (12,186)

    Basic and diluted net loss per common share

    $

    (0.23)



    $

    (0.20)

    Shares used in calculation of basic and diluted net loss per common

    share:

    76,367



    62,461

     

    Balance Sheet Data (unaudited):



    (amounts in thousands)





    March 31,



    December 31,





    2021



    2020

    Cash and cash equivalents



    $

    33,105



    $

    40,394

    Short-term investments



    4,060



    12,057

    Working capital



    23,790



    37,287

    Total assets



    42,789



    58,241

    Current portion of long-term debt



    3,252



    4,455

    Total stockholders' equity



    26,654



    40,029

     

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-reports-first-quarter-2021-financial-results-301302599.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  15. SEATTLE, June 1, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia (platelet counts less than 50 x 109/L), with the NDA being granted Priority Review. The Prescription Drug User Fee Act (PDUFA) target action date is November 30, 2021. The FDA is not currently planning to hold an advisory committee meeting to discuss the NDA.

    "We are pleased that the FDA's acceptance of our NDA brings us one step closer to our goal of providing myelofibrosis patients with severe thrombocytopenia a new treatment option," said Adam R. Craig, M.D., Ph.D., President…

    SEATTLE, June 1, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia (platelet counts less than 50 x 109/L), with the NDA being granted Priority Review. The Prescription Drug User Fee Act (PDUFA) target action date is November 30, 2021. The FDA is not currently planning to hold an advisory committee meeting to discuss the NDA.

    "We are pleased that the FDA's acceptance of our NDA brings us one step closer to our goal of providing myelofibrosis patients with severe thrombocytopenia a new treatment option," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI Biopharma. "With commercial preparation underway, we believe we will be well positioned for a potential U.S. launch later this year. We look forward to working with the FDA during its review of our application."

    The NDA was accepted based on the data from the Phase 3 PERSIST-2 and PERSIST-1 and the Phase 2 PAC203 clinical trials, with a focus on the severely thrombocytopenic (platelet counts less than 50 x 109/L) patients enrolled in these studies who received pacritinib 200 mg twice a day, including both frontline treatment-naive patients and patients with prior exposure to JAK2 inhibitors. In the PERSIST-2 study, in patients with severe thrombocytopenia who were treated with pacritinib 200 mg twice a day, 29% of patients had a reduction in spleen volume of at least 35%, compared to 3% of patients receiving the best available therapy, which included ruxolitinib.; 23% of patients had a reduction in total symptom scores of at least 50%, compared to 13% of patients receiving the best available therapy. In the same population of patients treated with pacritinib, adverse events were generally low grade, manageable with supportive care, and rarely led to discontinuation. Platelet counts and hemoglobin levels were also stabilized.

    About Myelofibrosis and Severe Thrombocytopenia

    Myelofibrosis is a type of bone marrow cancer that results in formation of fibrous scar tissue and can lead to severe thrombocytopenia and anemia, weakness, fatigue and enlarged spleen and liver. Patients with severe thrombocytopenia are estimated to make up one-third of patients treated for myelofibrosis, or approximately 17,000 people in the United States and Europe. Severe thrombocytopenia, defined as blood platelet counts of less than 50 x 109/L, has been shown to result in overall survival rates of just 15 months. Thrombocytopenia in patients with myelofibrosis is associated with the underlying disease but has also been shown to result from treatment with ruxolitinib, which can lead to dose reductions, and as a result, may potentially reduce clinical benefit. Survival in patients who have discontinued ruxolitinib therapy is further compromised, with an average overall survival of seven to 14 months. Myelofibrosis patients with severe thrombocytopenia have limited treatment options, and represent an area of significant area of unmet medical need.

    About Pacritinib

    Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, IRAK1, and CSF1R, but not JAK1. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia, and lymphoma. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and chronic lymphocytic leukemia (CLL), due to its inhibition of c-fms, IRAK1, JAK2 and FLT.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis, and in response to the COVID pandemic, severe COVID-19 disease. We are headquartered in Seattle, Washington.

    Forward-Looking Statements

    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to the timing and likelihood of regulatory filings and approvals for pacritinib; whether the FDA determines that additional trials or data are necessary in order to obtain approval; the potential market size and the size of the patient populations for pacritinib, if approved for commercial use; the market opportunities for pacritinib; and those risks more fully discussed in the section entitled "Risk Factors" in CTI's Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:

    Argot Partners

    +212-600-1902

    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-acceptance-of-nda-granted-with-priority-review-of-pacritinib-for-treatment-of-patients-with-myelofibrosis-301302627.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  16. SEATTLE, May 26, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to six new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on May 26, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 240,000 shares of CTI BioPharma common stock. The options will be issued upon each employee's commencement of employment (the "Grant Date"), and all stock options included within the equity inducement awards will have an exercise price equal to the closing price of CTI BioPharma common stock on each respective Grant Date. One-fourth of the options will vest on each anniversary of the employee's Grant Date, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301300281.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  17. SEATTLE, May 12, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on May 12, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 90,000 shares of CTI BioPharma common stock. The options will be issued upon each employee's commencement of employment (the "Grant Date"), and all stock…

    SEATTLE, May 12, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on May 12, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 90,000 shares of CTI BioPharma common stock. The options will be issued upon each employee's commencement of employment (the "Grant Date"), and all stock options included within the equity inducement awards will have an exercise price equal to the closing price of CTI BioPharma common stock on each respective Grant Date. One-fourth of the options will vest on each anniversary of the employee's Grant Date, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301290382.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  18. SEATTLE, May 5, 2021 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ:CTIC) today announced that management plans to report its first quarter 2021 financial results on Tuesday, June 1, 2021, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT).

    To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 9343326. A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com. A replay of the webcast will be available for 30 days following the event.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Argot Partners

    +212-600-1902

    cti@argotpartners.com

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-report-first-quarter-2021-financial-results-on-june-1-2021-301283960.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  19. SEATTLE, April 21, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on April 21, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 80,000 shares of CTI BioPharma common stock. The options will be issued upon each employee's commencement of employment (the "Grant Date"), and all…

    SEATTLE, April 21, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on April 21, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 80,000 shares of CTI BioPharma common stock. The options will be issued upon each employee's commencement of employment (the "Grant Date"), and all stock options included within the equity inducement awards will have an exercise price equal to the closing price of CTI BioPharma common stock on each respective Grant Date. One-fourth of the options will vest on each anniversary of the employee's Grant Date, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301274447.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  20. SEATTLE, April 7, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that management will provide a corporate overview at the 20th Annual Needham Virtual Healthcare Conference at 3:00 p.m. EST. The conference will be held in a virtual meeting format.

    Presentation details:

    Event: 20th Annual Needham Virtual Healthcare Conference

    Date: Wednesday, April 14, 2021

    Time: 3:00 p.m. EST

    The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-20th-annual-needham-virtual-healthcare-conference-on-wednesday-apr-14-301263743.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  21. SEATTLE, April 2, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to three new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on April 1, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 107,500 shares of CTI BioPharma common stock. The options will be issued upon each employee's commencement of employment (the "Grant Date"), and all stock options included within the equity inducement awards will have an exercise price equal to the closing price of CTI BioPharma common stock on each respective Grant Date. One-fourth of the options will vest on each anniversary of the employee's Grant Date, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301261574.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  22. SEATTLE, March 31, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) ("CTI"), a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers, today announced the pricing of its previously announced underwritten public offering of 14,260,800 shares of its common stock and 600 shares of its series X1 preferred stock (the "Series X1 Preferred"). In addition, CTI has granted the underwriters a 30-day option to purchase up to an additional 2,139,120 shares of its common stock on the same terms and conditions. The offering price to the public of a share of common stock is $2.50 and the offering price to the public of a share of Series X1 Preferred…

    SEATTLE, March 31, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) ("CTI"), a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers, today announced the pricing of its previously announced underwritten public offering of 14,260,800 shares of its common stock and 600 shares of its series X1 preferred stock (the "Series X1 Preferred"). In addition, CTI has granted the underwriters a 30-day option to purchase up to an additional 2,139,120 shares of its common stock on the same terms and conditions. The offering price to the public of a share of common stock is $2.50 and the offering price to the public of a share of Series X1 Preferred Stock is $25,000. Each share of Series X1 Preferred will be convertible into 10,000 shares of common stock at the election of the holder, subject to beneficial ownership conversion limits applicable to the Series X1 Preferred. 

    All of the securities in the offering are being sold by CTI. The gross proceeds to CTI from this underwritten public offering are expected to be approximately $50.7 million, before deducting the underwriting discount and other estimated offering expenses payable by CTI. The offering is expected to close on or about April 6, 2021, subject to the satisfaction of customary closing conditions.

    CTI intends to use the proceeds from the proposed sale of its shares of common stock and Series X1 Preferred Stock for commercialization activities for pacritinib, general working capital and corporate purposes.

    Stifel and JMP Securities are acting as joint book-running managers for the offering. BTIG is acting as lead manager for the offering.

    The offering is being made pursuant to a registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission (the "SEC") and subsequently was declared effective by the SEC. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering has been filed with the SEC and a final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's web site at www.sec.gov. When available, copies of the final prospectus relating to these securities may be obtained by sending a request to Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery St, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com, or JMP Securities LLC, 600 Montgomery St, Suite 1100, San Francisco, CA 94111, Attn: Prospectus Department, telephone: 415-835-8900.  

    This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

    About CTI BioPharma Corp.

    CTI is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI concentrates its efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, CTI is focused on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. In addition, CTI is developing pacritinib for use in the prevention of acute graft versus host disease and in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. CTI is headquartered in Seattle, Washington.

    Forward-Looking Statements

    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the impact of general market, economic, industry or political conditions in the United States or internationally; the satisfaction of customary closing conditions related to the proposed public offering; CTI's capital position and the sufficiency of its capital to fund its operations in future periods; and those risks more fully discussed in the section entitled "Risk Factors" in CTI's Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent quarterly reports on Form 10-Q. CTI will continue to need significant additional capital to fund its operations and may be unable to raise capital when needed, which would force CTI to delay, reduce or eliminate its commercialization activities for pacritinib. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-corp-announces-pricing-of-its-public-offering-of-common-stock-and-preferred-stock-301260258.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  23. SEATTLE, March 31, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) ("CTI"), a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers, today announced that it intends to offer and sell shares of its common stock and series X1 preferred stock (the "Series X1 Preferred") in an underwritten registered public offering. All of the securities in the proposed offering are to be sold by CTI. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Each share of Series X1 Preferred will be convertible into 10,000 shares of common…

    SEATTLE, March 31, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) ("CTI"), a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers, today announced that it intends to offer and sell shares of its common stock and series X1 preferred stock (the "Series X1 Preferred") in an underwritten registered public offering. All of the securities in the proposed offering are to be sold by CTI. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Each share of Series X1 Preferred will be convertible into 10,000 shares of common stock at the election of the holder, subject to beneficial ownership conversion limits applicable to the Series X1 Preferred. 

    CTI intends to use the proceeds from the proposed sale of its shares of common stock and Series X1 Preferred Stock for commercialization activities for pacritinib, general working capital and corporate purposes.

    Stifel and JMP Securities are acting as joint book-running managers for the offering. BTIG is acting as lead manager for the offering.

    The offering is being made pursuant to a registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission (the "SEC") and subsequently was declared effective by the SEC. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC. Copies of the preliminary prospectus supplement and accompanying prospectus relating to these securities may also be obtained by sending a request to Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery St, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com, or JMP Securities LLC, 600 Montgomery St, Suite 1100, San Francisco, CA 94111, Attn: Prospectus Department, telephone: 415-835-8900.  

    This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

    About CTI BioPharma Corp.

    CTI is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI concentrates its efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, CTI is focused on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. In addition, CTI is developing pacritinib for use in the prevention of acute graft versus host disease and in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. CTI is headquartered in Seattle, Washington.

    Forward-Looking Statements

    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: whether or not CTI will be able to raise capital through the sale of its securities; the final terms of the proposed offering; the impact of general market, economic, industry or political conditions in the United States or internationally; the satisfaction of customary closing conditions related to the proposed public offering; CTI's capital position and the sufficiency of its capital to fund its operations in future periods; and those risks more fully discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent quarterly reports on Form 10-Q. There can be no assurance that CTI will be able to complete the proposed public offering on acceptable terms, or at all. CTI will continue to need significant additional capital to fund its operations and may be unable to raise capital when needed, which would force CTI to delay, reduce or eliminate its commercialization activities for pacritinib. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-corp-announces-proposed-public-offering-of-common-stock-and-preferred-stock-301260056.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  24. SEATTLE, March 31, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it has completed a rolling New Drug Application ("NDA") submission to the U.S. Food and Drug Administration ("FDA") seeking approval of pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia (platelet counts less than 50 x 109/L). CTI had previously announced the results of a pre-NDA meeting with FDA where agreement was reached on an NDA submission package based upon available data from the completed Phase 3 PERSIST-1 and PERSIST-2 trials and the Phase 2 PAC203 trials.

    "The completion of the pacritinib NDA submission is the result of many years of clinical research and a collaborative and constructive dialogue with the FDA on how pacritinib could address the unmet medical need of myelofibrosis ("MF") patients with severe thrombocytopenia. MF patients with severe thrombocytopenia experience poor treatment outcomes, primarily due to their severely cytopenic disease and the significant limitations of approved therapies," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI BioPharma. "CTI has initiated pre-commercialization activities and has completed the hiring of a commercial leadership team. Assuming a successful priority review of the NDA, we are preparing for a commercial launch of pacritinib before the end of 2021. We look forward to providing updates on the NDA and our commercialization plans over the coming months."

    About Myelofibrosis and Severe Thrombocytopenia

    Myelofibrosis is a type of bone marrow cancer that results in formation of fibrous scar tissue and can lead to severe cytopenias, including thrombocytopenia and anemia, as well as weakness, fatigue and an enlarged spleen and liver. Patients with severe thrombocytopenia are estimated to make up more than one-third of patients treated for myelofibrosis, or approximately 17,000 people in the United States and Europe. Severe thrombocytopenia, defined as blood platelet counts of less than 50,000 per microliter, has been shown to result in overall survival rates of just 15 months. Thrombocytopenia in patients with myelofibrosis is associated with the underlying disease but has also been shown to correlate with treatment with ruxolitinib, which can lead to dose reductions, and as a result, may potentially reduce clinical benefit. Survival in patients who have discontinued ruxolitinib therapy is further compromised, with an average overall survival of seven to 14 months. Myelofibrosis patients with severe thrombocytopenia have limited treatment options, creating a significant area of unmet medical need.

    About Pacritinib

    Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, IRAK1, and CSF1R. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia, and lymphoma. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and chronic lymphocytic leukemia (CLL), due to its inhibition of c-fms, IRAK1, JAK2 and FLT3.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. In addition, are developing pacritinib for use the prevention of acute graft versus host disease and in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    Forward-Looking Statements

    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to conduct and complete clinical trials in our currently anticipated timeframes; our ability to successfully demonstrate the safety and efficacy of pacritinib; our expectations regarding the completion and outcome of our PACIFICA Phase 3 trial and our PRE-VENT Phase 3 trial; the risk that the FDA may determine that the benefit/risk profile of pacritinib at the dose selected for the PACIFICA Phase 3 trial does not support approval; the risk that the FDA may determine that the benefit/risk profile of pacritinib in the PRE-VENT Phase 3 trial does not support approval or requires additional clinical data for approval; the risk that pacritinib may fail in its development through our PACIFICA and PRE-VENT trial; our ability to receive regulatory approval for pacritinib pursuant to the accelerated approval pathway or at all; the risk that pacritinib may be delayed to a point where it is not commercially viable; the accuracy of our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations; risks and uncertainties related to the COVID-19 pandemic as it relates to our operations and ongoing clinical trials; and those risks more fully discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent reports filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

     

    Photo: https://mma.prnewswire.com/media/92552/cell_therapeutics_inc_cti_biopharma_corp_logo.jpg

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-completion-of-rolling-submission-of-new-drug-application-nda-for-pacritinib-in-myelofibrosis-patients-with-severe-thrombocytopenia-301259357.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  25. SEATTLE, March 22, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), today announced that Clinical Cancer Research, a journal of the American Association for Cancer Research, has published results from a Phase 1 study led by Joseph Pidala, MD, PhD (Moffitt Cancer Center), and Brian C. Betts, MD (Masonic Cancer Center at the University of Minnesota), evaluating pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, for the prevention of acute graft-versus-host disease (GVHD). The results demonstrated that pacritinib, combined with sirolimus and low-dose tacrolimus (PAC/SIR/TAC), has a promising safety profile and exhibits preliminary therapeutic activity in preventing acute GVHD after allogeneic hematopoietic…

    SEATTLE, March 22, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), today announced that Clinical Cancer Research, a journal of the American Association for Cancer Research, has published results from a Phase 1 study led by Joseph Pidala, MD, PhD (Moffitt Cancer Center), and Brian C. Betts, MD (Masonic Cancer Center at the University of Minnesota), evaluating pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, for the prevention of acute graft-versus-host disease (GVHD). The results demonstrated that pacritinib, combined with sirolimus and low-dose tacrolimus (PAC/SIR/TAC), has a promising safety profile and exhibits preliminary therapeutic activity in preventing acute GVHD after allogeneic hematopoietic cell transplantation. The article, titled "Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase 1 Trial Results," is available online (http://clincancerres.aacrjournals.org/content/early/2021/03/17/1078-0432.CCR-20-4725). The Phase 2 portion of the trial (NCT02891603) designed to evaluate the therapeutic effect of pacritinib in combination with sirolimus and low-dose tacrolimus for GVHD prevention is ongoing at Moffitt Cancer Center and the Masonic Cancer Center at the University of Minnesota.

    The Phase 1 portion of the trial (NCT02891603) evaluated the safety of pacritinib when administered with sirolimus plus low-dose tacrolimus after allogeneic hematopoietic cell transplantation (alloHCT). A 3+3 dose escalation design identified PAC 100 mg twice a day as the minimum biologically active and well-tolerated dose for further study. At this dose, one out of six study participants treated with the investigational regimen had Grade 2-4 acute GVHD. Chronic GVHD was rare, with only two participants developing mild disease per NIH consensus criteria, which resolved without systemic immune suppression.

    The new manuscript reports that dual JAK2/mTOR inhibition suppresses pathogenic Th1 and Th17 cells, enhances the potency of immunosuppressive regulatory T cells (Tregs), and maintains natural killer cells and CD8+ cytotoxic T lymphocytes required for graft-versus-leukemia. Importantly, PAC/SIR/TAC was observed to preserve donor cytomegalovirus (CMV) immunity, permit timely engraftment, and avoid cytopenias observed with nonselective JAK inhibitors.

    "The PAC/SIR/TAC regimen provides concurrent inhibition of JAK2 and mTOR, effectively suppressing donor T cell costimulation and IL-6 signal transduction implicated in acute GVHD, while sparing STAT5 activation critical for immune tolerance and donor anti-leukemia immunity," said Brian C. Betts, MD, Associate Professor of Medicine in the Division of Hematology, Oncology, and Transplantation at the University of Minnesota. "The favorable safety profile to date and its impact on immune reconstitution after alloHCT make the PAC/SIR/TAC regimen a promising strategy to prevent GVHD. We are excited to continue to investigate the use of pacritinib in this important area of unmet need."

    "This Phase 1 clinical trial is the first study to demonstrate that combining pacritinib, a selective JAK2 inhibitor, with sirolimus-based GVHD prophylaxis may produce lower rates of acute GVHD compared to the reported rates for sirolimus and tacrolimus alone," said Adam. R. Craig, MD, PhD, President and Chief Executive Officer of CTI BioPharma. "We are encouraged by these data and look forward to further evaluating pacritinib in preventing GVHD in the on-going Phase 2 clinical trial and continuing to highlight the potential for the expanded use of pacritinib."

    About Pacritinib

    Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, IRAK1, and CSF1R. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia, and lymphoma. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and chronic lymphocytic leukemia (CLL), due to its inhibition of c-fms, IRAK1, JAK2 and FLT3.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    About the Masonic Cancer Center, University of Minnesota

    The Masonic Cancer Center, University of Minnesota, is the Twin Cities' only Comprehensive Cancer Center, designated 'Outstanding' by the National Cancer Institute. As Minnesota's Cancer Center, we have served the entire state for more than 25 years. Our researchers, educators, and care providers have worked to discover the causes, prevention, detection, and treatment of cancer and cancer-related diseases. Learn more at cancer.umn.edu.

    About Moffitt Cancer Center

    Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 51 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's scientific excellence, multidisciplinary research, and robust training and education. Moffitt is the No. 11 cancer hospital and has been nationally ranked by U.S. News & World Report since 1999. Moffitt's expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 7,000 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on FacebookTwitterInstagram and YouTube

    CTI BioPharma Forward-Looking Statements

    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to successfully demonstrate the safety and efficacy of pacritinib in various indications across multiple clinical trials; and those risks more fully discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

    "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/phase-1-trial-demonstrates-encouraging-clinical-benefit-and-promising-safety-profile-of-pacritinib-for-the-prevention-of-graft-versus-host-disease-published-in-clinical-cancer-research-301252886.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  26. SEATTLE, March 17, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the fourth quarter and full year ended December 31, 2020.

    "This past quarter, CTI has executed on the critical clinical, regulatory and commercial activities that will allow for the potential U.S. approval and commercial launch of pacritinib in 2021," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI Biopharma. "We continue to work diligently on our rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for pacritinib, for use in myelofibrosis patients with severe thrombocytopenia, and are on track to complete the submission before the end of this month. Pending priority…

    SEATTLE, March 17, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the fourth quarter and full year ended December 31, 2020.

    "This past quarter, CTI has executed on the critical clinical, regulatory and commercial activities that will allow for the potential U.S. approval and commercial launch of pacritinib in 2021," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI Biopharma. "We continue to work diligently on our rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for pacritinib, for use in myelofibrosis patients with severe thrombocytopenia, and are on track to complete the submission before the end of this month. Pending priority review and approval by the FDA, we are planning to launch pacritinib in the United States by the end of the year. Over the last quarter, we have focused on the key pre-commercial activities that will enable a successful launch, including the recruitment of key leadership roles in marketing and sales,  and the initiation of our disease awareness, market access, and field force strategies. We look forward to being able to provide pacritinib to myelofibrosis patients who are underserved by existing therapies."

    Expected Milestones

    • Expected completion of rolling NDA submission for pacritinib in myelofibrosis patients with severe thrombocytopenia – Q1 2021
    • Expected FDA approval and U.S. commercial launch of pacritinib in myelofibrosis patients with severe thrombocytopenia – by end of 2021
    • Reporting of interim analysis from the Phase 3 PRE-VENT trial in hospitalized patients with severe COVID-19 – mid-2021

    Fourth Quarter Financial Results

    Operating loss was $14.8 million and $47.8 million for the three months and year ended December 31, 2020, respectively, as compared to an operating loss of $9.5 million and $40.7 million for the respective periods in 2019. The increase in operating loss for the three months ended December 31, 2020, as compared to the comparable period in 2019, resulted primarily from more extensive research and development activities. The increase in operating loss for the year ended December 31, 2020, as compared to the comparable period in 2019, resulted primarily from the recording of a full allowance against certain VAT receivables due to a reduced certainty of their collectability.

    No revenues were recognized for the three months and year ended December 31, 2020 or for the three months ended December 31, 2019, as compared to revenues of $3.3 million recognized for the year ended December 31, 2019. License and contract revenues in 2019 resulted from royalty and other payments received from Les Laboratoires Servier and Institut de Recherches Internationales Servier ("Servier") and were related to the asset purchase agreement and transition period activities pursuant to the terms of the Termination and Transfer Agreement with Servier.

    Net loss for the three months ended December 31, 2020 was $15.0 million, or $0.20 for basic and diluted loss per share, as compared to a net loss of $8.2 million, or $0.14 for basic and diluted loss per share, for the same period in 2019. Net loss for the year ended December 31, 2020 was $52.5 million, or $0.74 for basic and diluted loss per share, as compared to a net loss of $40.0 million, or $0.69 for basic and diluted loss per share, for the same period in 2019.

    As of December 31, 2020, cash, cash equivalents and short-term investments totaled $52.5 million, as compared to $33.7 million as of December 31, 2019. We expect our current cash, cash equivalents and short-term investments will enable us to fund our operations into the second quarter of 2021.

    Conference Call and Webcast

    CTI will host a conference call and webcast to review its fourth quarter 2020 financial results and provide an update on business activities today, March 17 at 4:30 PM ET. To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 9095063. A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com. A replay of the webcast will be available for 30 days following the event.

    About Myelofibrosis and Severe Thrombocytopenia

    Myelofibrosis is a type of bone marrow cancer that results in formation of fibrous scar tissue and can lead to severe thrombocytopenia and anemia, weakness, fatigue and enlarged spleen and liver. Patients with severe thrombocytopenia are estimated to make up more than one-third of patients treated for myelofibrosis, or approximately 17,000 people in the United States and Europe. Severe thrombocytopenia, defined as blood platelet counts of less than 50,000 per microliter, has been shown to result in overall survival rates of just 15 months. Thrombocytopenia in patients with myelofibrosis is associated with the underlying disease but has also been shown to correlate with treatment with ruxolitinib, which can lead to dose reductions, and as a result, may potentially reduce clinical benefit. Survival in patients who have discontinued ruxolitinib therapy is further compromised, with an average overall survival of seven to 14 months. Myelofibrosis patients with severe thrombocytopenia have limited treatment options, creating a significant area of unmet medical need.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    Forward-Looking Statements

    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to conduct and complete clinical trials in our currently anticipated timeframes; our ability to successfully demonstrate the safety and efficacy of pacritinib; our expectations regarding the completion and outcome of our PACIFICA Phase 3 trial and our PRE-VENT Phase 3 trial; the risk that the FDA may determine that the benefit/risk profile of pacritinib at the dose selected for the PACIFICA Phase 3 trial does not support approval; the risk that the FDA may determine that the benefit/risk profile of pacritinib in the PRE-VENT Phase 3 trial does not support approval or requires additional clinical data for approval; the risk that pacritinib may fail in its development through our PACIFICA and PRE-VENT trial; our receipt of priority review by the FDA of our pending NDA; our ability to receive regulatory approval for pacritinib pursuant to the accelerated approval pathway or at all; the risk that pacritinib may be delayed to a point where it is not commercially viable; the accuracy of our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations; risks and uncertainties related to the COVID-19 pandemic as it relates to our operations and ongoing clinical trials; and those risks more fully discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    (tables follow)

     

    CTI BioPharma Corp.

    Condensed Consolidated Statements of Operations

    (In thousands, except per share amounts)

    (unaudited)





    Three Months Ended

     December 31,



    Twelve Months Ended

     December 31,



    2020



    2019



    2020



    2019

    License and contract revenues

    $





    $





    $





    $

    3,345



    Operating costs and expenses:















    Research and development

    9,486





    4,981





    25,943





    24,107



    General and administrative

    5,310





    4,493





    17,626





    19,155



    Restructuring expenses













    794



    Other operating expenses









    4,200







    Total operating costs and expenses

    14,796





    9,474





    47,769





    44,056



    Loss from operations

    (14,796)





    (9,474)





    (47,769)





    (40,711)



    Non-operating income (expense):















    Interest income

    17





    169





    204





    1,172



    Interest expense

    (92)





    (199)





    (511)





    (1,002)



    Amortization of debt discount and issuance costs

    (130)





    (130)





    (521)





    (521)



    Foreign exchange (loss) gain

    (1)





    128





    (80)





    (281)



    Gain (loss) on dissolution of subsidiary





    1,320





    (3,774)





    1,320



    Total non-operating (expense) income, net

    (206)





    1,288





    (4,682)





    688



    Net loss before noncontrolling interest

    (15,002)





    (8,186)





    (52,451)





    (40,023)



    Noncontrolling interest





    (2)









    3



    Net loss

    $

    (15,002)





    $

    (8,188)





    $

    (52,451)





    $

    (40,020)



    Basic and diluted net loss per common share

    $

    (0.20)





    $

    (0.14)





    $

    (0.74)





    $

    (0.69)



    Shares used in calculation of basic and diluted net loss per common

    share:

    74,640





    57,974





    71,141





    57,974









    Balance Sheet Data (unaudited):



    (amounts in thousands)





    December 31,



    December 31,





    2020



    2019

    Cash and cash equivalents



    $

    40,394





    $

    31,144



    Short-term investments



    12,057





    2,522



    Working capital



    37,287





    17,092



    Total assets



    58,241





    46,280



    Current portion of long-term debt



    4,455





    4,812



    Long-term debt, less current portion







    4,455



    Total stockholders' equity



    40,029





    17,930



     

     

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-reports-fourth-quarter-and-full-year-2020-financial-results-301249585.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  27. SEATTLE, March 12, 2021 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ:CTIC) today announced that management plans to report its fourth quarter and full year 2020 financial results on Wednesday, March 17, 2021, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT).

    To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 9095063. A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com. A replay of the webcast will be available for 30 days following the event.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-report-fourth-quarter-and-full-year-2020-financial-results-on-march-17-2021-301246156.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  28. SEATTLE, March 8, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees with a grant date of March 8, 2021, as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on March 8, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 80,000 shares of CTI BioPharma common stock. The options have an exercise price of $3.07, which is equal to the closing price of CTI BioPharma common stock on March 8, 2021, the grant date of the awards. One-fourth of the options will vest on each anniversary of the employee's date of hire, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301242908.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  29. SEATTLE, Feb. 25, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that management will provide a corporate overview at the Cowen 41st Annual Health Care Conference at 12:10 p.m. EST. The conference will be held in a virtual meeting format.

    Presentation details:

    Event: Cowen 41st Annual Health Care Conference

    Date: Thursday, Mar. 4, 2021

    Time: 12:10 p.m. EST

    The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-cowen-41st-annual-health-care-conference-on-thursday-mar-4-301235382.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  30. SEATTLE, Feb. 24, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to three new employees with a grant date of February 24, 2021, as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company.  The equity awards were approved on February 24, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 92,000 shares of CTI BioPharma common stock.  The options have an exercise price of $3.18, which is equal…

    SEATTLE, Feb. 24, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to three new employees with a grant date of February 24, 2021, as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company.  The equity awards were approved on February 24, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 92,000 shares of CTI BioPharma common stock.  The options have an exercise price of $3.18, which is equal to the closing price of CTI BioPharma common stock on February 24, 2021, the grant date of the awards. One-fourth of the options will vest on each anniversary of the employee's date of hire, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301235079.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  31. SEATTLE, Feb. 10, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees with a grant date of February 10, 2021, as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on February 10, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 160,000 shares of CTI BioPharma common stock. The options have an exercise price of $3.45, which is equal…

    SEATTLE, Feb. 10, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees with a grant date of February 10, 2021, as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on February 10, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 160,000 shares of CTI BioPharma common stock. The options have an exercise price of $3.45, which is equal to the closing price of CTI BioPharma common stock on February 10, 2021, the grant date of the awards. One-fourth of the options will vest on each anniversary of the employee's date of hire, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301226569.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  32. SEATTLE, Jan. 28, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees with a grant date of January 28, 2021, as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company.  The equity awards were approved on January 28, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 200,000 shares of CTI BioPharma common stock.  The options have an exercise price of $3.30, which is equal…

    SEATTLE, Jan. 28, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees with a grant date of January 28, 2021, as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company.  The equity awards were approved on January 28, 2021, in accordance with Nasdaq Listing Rule 5635(c)(4).

    The employees received options to purchase an aggregate of 200,000 shares of CTI BioPharma common stock.  The options have an exercise price of $3.30, which is equal to the closing price of CTI BioPharma common stock on January 28, 2021, the grant date of the awards. One-fourth of the options will vest on each anniversary of the employee's date of hire, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301217858.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  33. SEATTLE, Dec. 8, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that management will provide a corporate overview at The JMP Securities Hematology Summit at 3:00 p.m. EST. The conference will be held in a virtual meeting format.

    Presentation details:

    Event: The JMP Securities Hematology Summit
    Date: Tuesday, Dec. 15
    Time: 3:00 p.m. EST

    The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

    About CTI BioPharma Corp.
    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We…

    SEATTLE, Dec. 8, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that management will provide a corporate overview at The JMP Securities Hematology Summit at 3:00 p.m. EST. The conference will be held in a virtual meeting format.

    Presentation details:

    Event: The JMP Securities Hematology Summit

    Date: Tuesday, Dec. 15

    Time: 3:00 p.m. EST

    The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-jmp-securities-hematology-summit-on-tuesday-dec-15-301187816.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  34. SEATTLE, Dec. 6, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced an oral presentation supporting the Company's pacritinib development program in the prevention of acute graft versus host disease (GVHD) at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, being held virtually December 5-8, 2020. The results are from an investigator-sponsored Phase 1/2 study conducted at the Mayo Clinic and Moffit Cancer Center.

    "The data presented today at ASH highlights the potential for the expanded use of pacritinib. Acute GVHD following allogeneic hematopoietic cell transplantation results in higher rates of morbidity and mortality, compromises the anti-leukemic response of the graft and occurs despite standard immunosuppressive prophylaxis, rendering it an area where new therapeutic options are needed," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI Biopharma. "These data demonstrate that in this Phase 1/2 study, adding pacritinib to the standard prophylaxis of sirolimus and low-dose tacrolimus resulted in a significant reduction in the expected acute GVHD rates in patients within the first 100 days of therapy as compared to historical data, without compromising transplantation outcomes and without any new safety concerns. We are encouraged by these data, and look forward to further evaluating pacritinib's efficacy and safety in this indication in the on-going Phase 2 clinical trial."

    All presentation materials will be available at ctibiopharma.com following the presentations.

    Biological and Clinical Impact of JAK2/mTOR Blockade in GVHD Prevention: Preclinical and Phase 1 / 2 Study Results

    Results from an investigator-sponsored (Mayo Clinic and Moffit Cancer Center) Phase 1/2 study of GVHD prophylaxis for allogeneic hematopoietic cell transplantation (alloHCT) using pacritinib, sirolimus, low-dose tacrolimus are being presented today, Sunday, December 6 at 10 a.m. PT in an oral presentation session.

    Abstract: No. 355

    Summary: This single-arm Phase 1/2 study (NCT02891603) tested the safety, pharmacodynamics and efficacy of pacritinib when administered with sirolimus plus low-dose tacrolimus (PAC/SIR/TAC) after alloHCT. A 3+3 dose escalation design was planned using three doses of pacritinib (100 mg QD, 100 mg BID, 200 mg BID) in combination with standard sirolimus and low-dose tacrolimus immunosuppressive therapy. Efficacy endpoints included acute GVHD (aGVHD) rate at day 100.

    PAC 100 mg twice daily (BID), dose level 2, was selected as the recommended Phase 2 dose based on its biological activity and safety profile. Preliminary evidence of the benefit of adding pacritinib to standard immunosuppressive therapy in reducing the rates of aGVHD was reported, with a 25% rate of grade 2-4 aGVHD across all dose cohorts, and 17% at the recommended Phase 2 dose of 100 mg BID, as compared to grade 2-4 aGVHD incidence rate of 43% expected with sirolimus plus low-dose tacrolimus administered alone1. No compromise in alloHCT outcome or major safety concerns were observed.  Futher, there was no evidence of cytopenias, impaired immune reconstitution, or cytomegalovirus (CMV) reactivation. A Phase 2 clinical trial to fully evaluate efficacy in GVHD prevention is ongoing (NCT02891603).

    About Pacritinib

    Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, IRAK1, and CSF1R. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia and lymphoma. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and chronic lymphocytic leukemia (CLL), due to its inhibition of c-fms, IRAK1, JAK2 and FLT3.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in the prevention of acute graft versus host disease and in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    Forward-Looking Statements

    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to successfully demonstrate the safety and efficacy of pacritinib in various indications; our ability to receive regulatory approval for pacritinib pursuant to the accelerated approval pathway or at all; our planned commercialization of pacritinib; our ability to enter into potential partnerships relating to our commercial launch of pacritinib; and those risks more fully discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

    "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    1. Pidala et al, Oral Presentation, Abstract 355, ASH 2020.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-presentation-of-data-supporting-pacritinibs-potential-benefit-in-preventing-acute-gvhd-at-the-62nd-american-society-of-hematology-meeting-301186889.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  35. SEATTLE, Nov. 30, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an article highlighting pacritinib data was published in Blood Advances. The article, titled "Determining the Recommended Dose of Pacritinib: Results from the PAC203 Phase 2 Dose-Finding Study in Patients with Advanced Myelofibrosis" is available online via this link.

    "Having recently announced the start of a rolling NDA submission for pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia, a patient population with reduced survival and limited therapeutic options, we continue to be committed to adding to the growing body of evidence underscoring the efficacy and safety profile of pacritinib," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI Biopharma. "As our application will consist of a data package from the PERSIST-1, PERSIST-2 and PAC203 Phase 2 trials, with the ongoing Phase 3 PACIFICA trial expected to be completed as a post-marketing commitment, the data published today support our belief that pacritinib has the potential to become an important treatment in this disease setting, pending regulatory approval."

    PAC203 Phase 2 was an open-label, randomized, dose-finding trial of pacritinib in patients with myelofibrosis who were previously treated with ruxolitinib. Patients were randomized 1:1:1 to pacritinib 100 mg daily (QD), 100 mg BID, or 200 mg BID. The trial demonstrated that pacritinib 200 mg BID had a favorable benefit risk profile. Spleen volume response (SVR) rates were highest among patients treated with pacritinib 200 mg BID who had a baseline platelet count of less than 50 x 109/L. Overall, the study data supported the selection of the pacritinib 200 mg BID for use in the ongoing Phase 3 PACIFICA study of pacritinib in patients with myelofibrosis with severe thrombocytopenia.

    About Pacritinib

    Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, IRAK1, and CSF1R. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia and lymphoma. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and chronic lymphocytic leukemia (CLL), due to its inhibition of c-fms, IRAK1, JAK2 and FLT3.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    Forward-Looking Statements

    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to successfully demonstrate the safety and efficacy of pacritinib; our ability to complete a rolling NDA for pacritinib in the timeline currently anticipated; our ability to receive regulatory approval for pacritinib pursuant to the accelerated approval pathway or at all; our planned commercialization of pacritinib; our ability to enter into potential partnerships relating to our commercial launch of pacritinib; and those risks more fully discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-publication-of-article-highlighting-pacritinib-data-from-the-pac203-phase-2-study-in-myelofibrosis-in-blood-advances-301181337.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  36. SEATTLE, Nov. 10, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the third quarter and nine months ended September 30, 2020.

    "This past quarter we made significant progress in our pacritinib development program. We recently announced the initiation of our rolling New Drug Application (NDA) submission for pacritinib in myelofibrosis patients with severe thrombocytopenia, following a productive Pre-NDA meeting with the U.S. Food and Drug Administration (FDA) on how pacritinib could address the unmet need of this population, which includes both front-line treatment-naïve patients and patients with prior exposure to JAK2 inhibitors," said Adam R. Craig, M.D., Ph.D. "The NDA submission package will…

    SEATTLE, Nov. 10, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the third quarter and nine months ended September 30, 2020.

    "This past quarter we made significant progress in our pacritinib development program. We recently announced the initiation of our rolling New Drug Application (NDA) submission for pacritinib in myelofibrosis patients with severe thrombocytopenia, following a productive Pre-NDA meeting with the U.S. Food and Drug Administration (FDA) on how pacritinib could address the unmet need of this population, which includes both front-line treatment-naïve patients and patients with prior exposure to JAK2 inhibitors," said Adam R. Craig, M.D., Ph.D. "The NDA submission package will be based on available data from the completed Phase 3 PERSIST-1 and PERSIST-2, and the Phase 2 PAC203 trials, and we expect to complete the submission in the first quarter of 2021. Additionally, we have started pre-commercial activities in preparation for a commercial launch in 2021, subject to priority review."

    Expected Milestones

    • Oral presentation of preclinical and Phase 1 trial data of pacritinib in acute graft-versus-host disease (GVHD) at American Society of Hematology (ASH) 2020 – December 6, 2020
    • Expected completion of rolling NDA submission for pacritinib in myelofibrosis patients with severe thrombocytopenia – Q1 2021
    • Reporting of interim analysis from the Phase 3 PRE-VENT trial in hospitalized patients with severe COVID-19 –First half of 2021

    Third Quarter Financial Results

    Operating loss was $11.0 million and $33.0 million for the three and nine months ended September 30, 2020, respectively, compared to an operating loss of $9.7 million and $31.2 million for the respective periods in 2019. Operating loss for the three months ended September 30, 2020 as compared to the comparable period in 2019 resulted primarily from a decrease in license and contract revenues. The increase in operating loss for the nine months ended September 30, 2020 as compared to the comparable period in 2019 resulted primarily from the recording of a full allowance against certain VAT receivables due to a reduced certainty of collectability.

    No revenues were recognized for the three and nine months ended September 30, 2020, while revenues of $2.3 million and $3.3 million, respectively, were recognized for the comparable periods in 2019. License and contract revenues in 2019 resulted from royalty and other revenues recognized from Les Laboratoires Servier and Institut de Recherches Internationales Servier ("Servier") and related to the asset purchase agreement and transition period activities pursuant to the terms of the Termination and Transfer Agreement with Servier.

    Net loss for the three months ended September 30, 2020 was $11.3 million, or $0.15 for basic and diluted loss per share, compared to net loss of $10.0 million, or $0.17 for basic and diluted loss per share, for the same period in 2019. Net loss for the nine months ended September 30, 2020 was $37.4 million, or $0.54 for basic and diluted loss per share, compared to net loss of $31.8 million, or $0.55 for basic and diluted loss per share, for the same period in 2019.

    As of September 30, 2020, cash, cash equivalents and short-term investments totaled $57.4 million, compared to $33.7 million as of December 31, 2019. We expect current cash, cash equivalents and short-term investments will enable us to fund our operations into the fourth quarter of 2021.

    Conference Call and Webcast

    CTI will host a conference call and webcast to review its third quarter 2020 financial results and provide an update on business activities today, November 10 at 4:30 PM ET. To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 5504037. A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com. A replay of the webcast will be available for 30 days following the event.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    Forward-Looking Statements

    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to conduct and complete clinical trials in our currently anticipated timeframes; our ability to successfully demonstrate the safety and efficacy of pacritinib; our expectations regarding the completion and outcome of our PACIFICA Phase 3 trial and our PRE-VENT Phase 3 trial; the risk that the FDA may determine that the benefit/risk profile of pacritinib at the dose selected for the PACIFICA Phase 3 trial does not support approval; the risk that the FDA may determine that the benefit/risk profile of pacritinib in the PRE-VENT Phase 3 trial does not support approval or requires additional clinical data for approval; the risk that pacritinib may fail in its development through our PACIFICA and PRE-VENT trial; our ability to submit a rolling NDA for pacritinib in the timeline currently anticipated; our ability to receive regulatory approval for pacritinib pursuant to the accelerated approval pathway or at all; the risk that pacritinib may be delayed to a point where it is not commercially viable; the accuracy of our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations; risks and uncertainties related to the COVID-19 pandemic as it relates to our operations and ongoing clinical trials; and those risks more fully discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    (tables follow)

    CTI BioPharma Corp.

    Condensed Consolidated Statements of Operations

    (In thousands, except per share amounts)

    (unaudited)





    Three Months Ended

     September 30,



    Nine Months Ended

     September 30,



    2020



    2019



    2020



    2019

    License and contract revenues

    $





    $

    2,289





    $





    $

    3,345



    Operating costs and expenses:















    Research and development

    6,994





    7,598





    16,457





    19,126



    General and administrative

    4,052





    4,403





    12,316





    14,662



    Restructuring expenses













    794



    Other operating expenses









    4,200







    Total operating costs and expenses

    11,046





    12,001





    32,973





    34,582



    Loss from operations

    (11,046)





    (9,712)





    (32,973)





    (31,237)



    Non-operating income (expense):















    Interest income

    25





    276





    187





    1,003



    Interest expense

    (115)





    (240)





    (419)





    (803)



    Amortization of debt discount and issuance costs

    (131)





    (131)





    (391)





    (391)



    Foreign exchange gain (loss)

    4





    (240)





    (79)





    (409)



    Loss on dissolution of majority-owned subsidiary









    (3,774)







    Total non-operating expense, net

    (217)





    (335)





    (4,476)





    (600)



    Net loss before noncontrolling interest

    (11,263)





    (10,047)





    (37,449)





    (31,837)



    Noncontrolling interest













    5



    Net loss

    $

    (11,263)





    $

    (10,047)





    $

    (37,449)





    $

    (31,832)



    Basic and diluted net loss per common share

    $

    (0.15)





    $

    (0.17)





    $

    (0.54)





    $

    (0.55)



    Shares used in calculation of basic and diluted net loss per common share:

    73,712





    57,974





    69,966





    57,973



     

    Balance Sheet Data (unaudited):



    (amounts in thousands)





    September 30,



    December 31,





    2020



    2019

    Cash and cash equivalents



    $

    45,301





    $

    31,144



    Short-term investments



    12,111





    2,522



    Working capital



    44,169





    17,092



    Total assets



    63,091





    46,280



    Current portion of long-term debt



    5,658





    4,812



    Long-term debt, less current portion







    4,455



    Total stockholders' equity



    46,819





    17,930



     

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-reports-third-quarter-2020-financial-results-301170192.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  37. SEATTLE, Nov. 4, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced an oral presentation supporting the Company's pacritinib development program in graft versus host disease (GVHD) at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, being held virtually December 5- 8, 2020.

    The details of the presentation are as follows:

    Abstract Title: Biological and Clinical Impact of JAK2/mTOR Blockade in GVHD Prevention: Preclinical and Phase I Trial Results
    Session Name: Clinical Allogeneic Transplantation; Acute and Chronic GVHD, Immune Reconstitution Phase I and II Trials
    Session Number: 722
    Session Date: Sunday, December 6, 2020
    Session Time: 9:30 a.m. - 11:00 a.m. PT
    Presentation Time: 10:00 a.m. PT
    Presenter:

    SEATTLE, Nov. 4, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced an oral presentation supporting the Company's pacritinib development program in graft versus host disease (GVHD) at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, being held virtually December 5- 8, 2020.

    The details of the presentation are as follows:

    Abstract Title: Biological and Clinical Impact of JAK2/mTOR Blockade in GVHD Prevention: Preclinical and Phase I Trial Results

    Session Name: Clinical Allogeneic Transplantation; Acute and Chronic GVHD, Immune Reconstitution Phase I and II Trials

    Session Number: 722

    Session Date: Sunday, December 6, 2020

    Session Time: 9:30 a.m. - 11:00 a.m. PT

    Presentation Time: 10:00 a.m. PT

    Presenter: Dr. Joseph Pidala

    A copy of the abstract is available here.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-oral-presentation-at-the-62nd-american-society-of-hematology-meeting-301166463.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  38. SEATTLE, Nov. 2, 2020 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ:CTIC) today announced that management plans to report its third quarter 2020 financial results on Tuesday, November 10, 2020, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT).

    To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 5504037. A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com. A replay of the webcast will be available…

    SEATTLE, Nov. 2, 2020 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ:CTIC) today announced that management plans to report its third quarter 2020 financial results on Tuesday, November 10, 2020, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT).

    To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 5504037. A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com. A replay of the webcast will be available for 30 days following the event.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

     

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-report-third-quarter-2020-financial-results-on-november-10-2020-301165190.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  39. SEATTLE, Oct. 13, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it has commenced a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration ("FDA" or "the Agency") seeking approval of pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia (platelet counts less than 50 x 109/L). CTI has previously announced the results of a recent Pre-NDA meeting with FDA where agreement was reached on an NDA submission package based upon available data from the completed Phase 3 PERSIST-1 and PERSIST-2, and the Phase 2 PAC203 trials.

    "Today we are pleased to announce the start of a rolling NDA submission that seeks to address the important unmet medical need of myelofibrosis…

    SEATTLE, Oct. 13, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it has commenced a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration ("FDA" or "the Agency") seeking approval of pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia (platelet counts less than 50 x 109/L). CTI has previously announced the results of a recent Pre-NDA meeting with FDA where agreement was reached on an NDA submission package based upon available data from the completed Phase 3 PERSIST-1 and PERSIST-2, and the Phase 2 PAC203 trials.

    "Today we are pleased to announce the start of a rolling NDA submission that seeks to address the important unmet medical need of myelofibrosis patients with severe thrombocytopenia, a population that includes both front-line treatment-naïve patients and patients with prior exposure to JAK2 inhibitors," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI Biopharma. "We have started pre-commercial activities and are planning for a commercial launch in 2021, subject to priority review."

    About Myelofibrosis and Severe Thrombocytopenia

    Myelofibrosis is a type of bone marrow cancer that results in formation of fibrous scar tissue and can lead to severe thrombocytopenia and anemia, weakness, fatigue and enlarged spleen and liver. Patients with severe thrombocytopenia are estimated to make up more than one-third of patients treated for myelofibrosis, or approximately 17,000 people in the United States and Europe. Severe thrombocytopenia, defined as blood platelet counts of less than 50,000 per microliter, has been shown to result in overall survival rates of just 15 months. Thrombocytopenia in patients with myelofibrosis is associated with the underlying disease but has also been shown to correlate with treatment with ruxolitinib, which can lead to dose reductions, and as a result, may potentially reduce clinical benefit. Survival in patients who have discontinued ruxolitinib therapy is further compromised, with an average overall survival of seven to 14 months. Myelofibrosis patients with severe thrombocytopenia have limited treatment options, creating a significant area of unmet medical need.

    About Pacritinib

    Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, IRAK1, and CSF1R. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia and lymphoma. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and chronic lymphocytic leukemia (CLL), due to its inhibition of c-fms, IRAK1, JAK2 and FLT3.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    Forward-Looking Statements

    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to successfully demonstrate the safety and efficacy of pacritinib; our ability to complete a rolling NDA for pacritinib in the timeline currently anticipated; our ability to receive regulatory approval for pacritinib pursuant to the accelerated approval pathway or at all; our planned commercialization of pacritinib; our ability to enter into potential partnerships relating to our commercial launch of pacritinib; and those risks more fully discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

     

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-initiates-rolling-submission-of-new-drug-application-nda-for-pacritinib-in-myelofibrosis-patients-with-severe-thrombocytopenia-301150876.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  40. SEATTLE, Sept. 29, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that following a recent Pre-NDA meeting with the U.S. Food and Drug Administration ("FDA" or "the Agency"), the Company has reached an agreement to submit an NDA for the potential accelerated approval of pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia (platelet count less than 50 x 109/L). The NDA will be based on the available data from the Company's completed Phase 3 PERSIST-1 and PERSIST-2 trials and the Phase 2 PAC203 dose-ranging trial. The FDA has agreed to a rolling NDA submission which is expected to commence within a few weeks, with completion of the NDA submission anticipated in the first quarter of 2021. The…

    SEATTLE, Sept. 29, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that following a recent Pre-NDA meeting with the U.S. Food and Drug Administration ("FDA" or "the Agency"), the Company has reached an agreement to submit an NDA for the potential accelerated approval of pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia (platelet count less than 50 x 109/L). The NDA will be based on the available data from the Company's completed Phase 3 PERSIST-1 and PERSIST-2 trials and the Phase 2 PAC203 dose-ranging trial. The FDA has agreed to a rolling NDA submission which is expected to commence within a few weeks, with completion of the NDA submission anticipated in the first quarter of 2021. The ongoing Phase 3 PACIFICA trial is expected to be completed as a post-marketing commitment.

    "Since the completion of the PAC203 Phase 2 dose-ranging trial, we have been working collaboratively with the FDA to identify an expeditious approval pathway for pacritinib in myelofibrosis patients with severe thrombocytopenia, a patient population with an important unmet medical need due to reduced survival and limited therapeutic options. During a recent Pre-NDA meeting, we identified a data package from the PERSIST-1, PERSIST-2 and PAC203 Phase 2 trials that will serve as the basis for an accelerated approval application. In particular, we discussed risk mitigation measures to address the FDA's prior concerns regarding safety," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI Biopharma. "In myelofibrosis patients, severe thrombocytopenia occurs as a result of disease or drug-related toxicity from current therapies. There is no approved drug that specifically addresses the unmet need of the myelofibrosis patients who have severe thrombocytopenia. Pacritinib has demonstrated clinical benefit in treating these patients in multiple trials and now has the potential to become a new treatment option for treatment-naïve and second-line myelofibrosis patients in 2021."   

    Conference Call and Webcast

    CTI will host a conference call and webcast to discuss this announcement tomorrow, September 30, 2020 at 8:30 AM ET. To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 9275344. A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com. A replay of the webcast will be available for 30 days following the event.

    About Myelofibrosis and Severe Thrombocytopenia

    Myelofibrosis is a type of bone marrow cancer that results in formation of fibrous scar tissue and can lead to severe anemia, weakness, fatigue and an enlarged spleen and liver. Patients with severe thrombocytopenia are estimated to make up more than one-third of patients treated for myelofibrosis, or approximately 17,000 people. Severe thrombocytopenia, defined as blood platelet counts of less than 50,000 per microliter, has been shown to result in overall survival rates of just 15 months. Thrombocytopenia in patients with myelofibrosis is associated with the underlying disease but has also been shown to correlate with treatment with ruxolitinib, which can lead to dose reductions, and as a result, may potentially reduce clinical benefit. Survival in patients who have discontinued ruxolitinib therapy is further compromised, with an average overall survival of seven to 14 months. Myelofibrosis patients with severe thrombocytopenia have limited treatment options, creating a significant area of unmet medical need.

    About Pacritinib

    Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia and lymphoma. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and chronic lymphocytic leukemia (CLL), due to its inhibition of c-fms, IRAK1, JAK2 and FLT3. 

    In March 2008, pacritinib received orphan drug designation for the treatment of primary myelofibrosis (MF), post-polycythemia vera MF, and post-essential thrombocythemia MF. 

    In August 2014, pacritinib was granted Fast Track designation by the FDA for the treatment of intermediate and high risk myelofibrosis, including, but not limited to,  patients with disease-related thrombocytopenia (low platelet counts); patients experiencing treatment-emergent thrombocytopenia on other JAK2 inhibitor therapy; or patients who are intolerant of or whose symptoms are not well controlled (sub-optimally managed) on other JAK2 therapy.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    Forward-Looking Statements

    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to conduct and complete clinical trials in our currently anticipated timeframes; our ability to successfully demonstrate the safety and efficacy of pacritinib; our expectations regarding the completion and outcome of our PACIFICA Phase 3 trial and our PRE-VENT Phase 3 trial; the risk that the FDA may determine that the benefit/risk profile of pacritinib at the dose selected for the PACIFICA Phase 3 trial does not support approval; the risk that the FDA may determine that the benefit/risk profile of pacritinib in the PRE-VENT Phase 3 trial does not support approval or requires additional clinical data for approval; the risk that pacritinib may fail in its development through our PACIFICA and PRE-VENT trial; our ability to submit a rolling NDA for pacritinib in the timeline currently anticipated; our ability to receive regulatory approval for pacritinib pursuant to the accelerated approval pathway or at all; the risk that pacritinib may be delayed to a point where it is not commercially viable; and those risks more fully discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-submit-a-new-drug-application-nda-for-the-accelerated-approval-of-pacritinib-for-the-treatment-of-myelofibrosis-patients-with-severe-thrombocytopenia-301140315.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  41. SEATTLE, Aug. 6, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the second quarter and six months ended June 30, 2020.

    "This past quarter we announced enrollment of the first patient in our PRE-VENT Phase 3 clinical trial of pacritinib in hospitalized patients with severe COVID-19, an important step for CTI as we work to provide a new therapeutic option for COVID-19 patients," said Adam R. Craig, M.D., Ph.D. "With regards to the PACIFICA Phase 3 trial, we continue to enroll patients but the enrollment rate is lower than planned due to the COVID-19 pandemic and we now anticipate at least a six-month delay in the trial.  However, given our cash runway into Q4 2021, we remain confident in our ability…

    SEATTLE, Aug. 6, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the second quarter and six months ended June 30, 2020.

    "This past quarter we announced enrollment of the first patient in our PRE-VENT Phase 3 clinical trial of pacritinib in hospitalized patients with severe COVID-19, an important step for CTI as we work to provide a new therapeutic option for COVID-19 patients," said Adam R. Craig, M.D., Ph.D. "With regards to the PACIFICA Phase 3 trial, we continue to enroll patients but the enrollment rate is lower than planned due to the COVID-19 pandemic and we now anticipate at least a six-month delay in the trial.  However, given our cash runway into Q4 2021, we remain confident in our ability to successfully execute on the development of pacritinib for the treatment of severely thrombocytopenic myelofibrosis patients."

    Second Quarter Financial Results

    Operating loss was $10.0 million and $21.9 million for the three and six months ended June 30, 2020, respectively, compared to operating loss of $11.0 million and $21.5 million for the respective periods in 2019. Operating loss for the three months ended June 30, 2020 as compared to the comparable period in 2019 resulted primarily from a decrease in general and administrative expenses. The increase in operating loss for the six months ended June 30, 2020 as compared to the comparable period in 2019 resulted primarily from the recording of a full allowance against certain VAT receivables due to an increased uncertainty of collectability.

    No revenues were recognized for the three and six months ended June 30, 2020, while revenues of $0.4 million and $1.1 million, respectively, were recognized for the comparable periods in 2019. License and contract revenues in 2019 resulted from royalty and other revenues recognized from Les Laboratoires Servier and Institut de Recherches Internationales Servier ("Servier") related to transition period activities pursuant to the terms of the Termination and Transfer Agreement with Servier.

    Net loss for the three months ended June 30, 2020 was $14.0 million, or $(0.19) for basic and diluted loss per share, compared to net loss of $11.0 million, or $(0.19) for basic and diluted loss per share, for the same period in 2019. Net loss for the six months ended June 30, 2020 was $26.2 million, or $(0.38) for basic and diluted loss per share, compared to net loss of $21.8 million, or $(0.38) for basic and diluted loss per share, for the same period in 2019.

    As of June 30, 2020, cash, cash equivalents and short-term investments totaled $70.1 million, compared to $33.7 million as of December 31, 2019. We expect current cash and cash equivalents will enable us to fund our operations into the fourth quarter of 2021.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

    Forward-Looking Statements

    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to conduct and complete clinical trials in our currently anticipated timeframes; our ability to successfully demonstrate the safety and efficacy of pacritinib; our expectations regarding the completion and outcome of our PACIFICA Phase 3 trial and our PRE-VENT Phase 3 trial; the risk that the FDA may determine that the benefit/risk profile of pacritinib at the dose selected for the PACIFICA Phase 3 trial does not support approval; the risk that the FDA may determine that the benefit/risk profile of pacritinib in the PRE-VENT Phase 3 trial does not support approval or requires additional clinical data for approval; the risk that pacritinib may fail in its development through our PACIFICA and PRE-VENT trial; our ability to submit an NDA for pacritinib in the timeline currently anticipated; our ability to receive regulatory approval for pacritinib pursuant to the accelerated approval pathway or at all; the risk that pacritinib may be delayed to a point where it is not commercially viable; the accuracy of our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations; risks and uncertainties related to the COVID-19 pandemic as it relates to our operations and ongoing clinical trials; and those risks more fully discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:

    Maeve Conneighton/Maghan Meyers

    +212-600-1902

    cti@argotpartners.com

    (tables follow)

    CTI BioPharma Corp.

    Condensed Consolidated Statements of Operations

    (In thousands, except per share amounts)

    (unaudited)

     



    Three Months Ended

     June 30,



    Six Months Ended

     June 30,



    2020



    2019



    2020



    2019

    License and contract revenues

    $





    $

    416





    $





    $

    1,056



    Operating costs and expenses:















    Research and development

    6,199





    6,356





    9,463





    11,528



    General and administrative

    3,797





    5,053





    8,264





    10,259



    Restructuring expenses













    794



    Other operating expenses









    4,200







    Total operating costs and expenses

    9,996





    11,409





    21,927





    22,581



    Loss from operations

    (9,996)





    (10,993)





    (21,927)





    (21,525)



    Non-operating income (expense):















    Interest income

    43





    347





    162





    727



    Interest expense

    (137)





    (269)





    (304)





    (563)



    Amortization of debt discount and issuance costs

    (130)





    (130)





    (260)





    (260)



    Foreign exchange (loss) gain

    (6)





    69





    (83)





    (169)



    Loss on dissolution of majority-owned subsidiary

    (3,774)









    (3,774)







    Total non-operating (expense) income, net

    (4,004)





    17





    (4,259)





    (265)



    Net loss before noncontrolling interest

    (14,000)





    (10,976)





    (26,186)





    (21,790)



    Noncontrolling interest





    5









    5



    Net loss

    $

    (14,000)





    $

    (10,971)





    $

    (26,186)





    $

    (21,785)



    Basic and diluted net loss per common share

    $

    (0.19)





    $

    (0.19)





    $

    (0.38)





    $

    (0.38)



    Shares used in calculation of basic and diluted net loss per common share:

    73,685





    57,973





    68,073





    57,973



     

    Balance Sheet Data (unaudited):



    (amounts in thousands)





    June 30,



    December 31,





    2020



    2019

    Cash and cash equivalents



    $

    70,110





    $

    31,144



    Short-term investments







    2,522



    Working capital



    57,782





    17,092



    Total assets



    76,412





    46,280



    Current portion of long-term debt



    4,812





    4,812



    Long-term debt, less current portion



    2,049





    4,455



    Total stockholders' equity



    56,863





    17,930



     

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-reports-second-quarter-2020-financial-results-301107949.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  42. SEATTLE, June 1, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of pacritinib in hospitalized patients with severe COVID-19. PRE-VENT, a randomized, double-blind, placebo-controlled multicenter study, will compare pacritinib plus standard of care versus placebo and standard of care in 358 hospitalized patients with severe COVID-19, including patients with and without cancer. The primary endpoint of the trial will assess the proportion of patients who progress to invasive mechanical ventilation and/or extracorporeal membrane oxygenation or die by Day 28.

    "Initiation of patient enrollment in the PRE-VENT Phase 3 trial is an important step for CTI as we work towards providing a new therapeutic option for patients with severe COVID-19," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI BioPharma. "As a multi-kinase inhibitor, pactrinib has the potential to reduce the effects of the cytokine storm that occurs with the novel coronavirus infection, an inflammatory response that frequently leads to respiratory failure and need for mechanical ventilation."

    "Preventing COVID-19 patients from developing the severe inflammatory response that leads to respiratory failure is critical as the medical community works to ameliorate the effects of the ongoing pandemic," said John Mascarenhas, M.D., Associate Professor, Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York and Chief Investigator of the PRE-VENT Study. "Because the cytokine storm occurs when multiple inflammatory cytokines are activated, including IL-1 and IL-6, a multi-kinase inhibitor such as pacritinib has the potential to inhibit the inflammatory response and improve patient outcomes."

    Cytokine storm is a pathological immune reaction that can be triggered by viral infection and can lead to serious complications, including acute respiratory distress syndrome (ARDS). Multiple inflammatory cytokines are upregulated in patients with severe COVID-19, including IL-1 and IL-6, and some patients have evidence of over-active macrophage activation. As a JAK2/IRAK-1 inhibitor, pacritinib may ameliorate the effects of cytokine storm via inhibition of IL-6 and IL-1 signaling. Furthermore, as a CSF-1R inhibitor, pacritinib may mitigate effects of macrophage activation syndrome. Of particular importance in this indication, pacritinib has not been associated with increased risk in infections in prior randomized studies, likely because it does not have inhibitory effects on JAK1.

    About PRE-VENT
    PRE-VENT is expected to enroll 358 patients randomized 1:1 to receive pacritinib (400 mg once daily on Day 1, then 200 mg twice daily from Day 2 to Day 14) + SOC or placebo + SOC. Assigned treatment will continue for up to Day 14 or until the patient experiences intolerable adverse events, withdraws consent, initiates another investigational therapy, or until the study is terminated. Assigned therapy may be given for an additional 7 days (for a total of 21 days) at the discretion of the investigator. In the event of hospital discharge, patients will complete treatment with the assigned therapy on an outpatient basis. Severe COVID-19 will be defined as an oxygen saturation (SO2) ≤93% on room air at sea level, respiratory frequency >30 breaths per minute, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300, or lung infiltrates >50% on radiographic imaging.

    The primary endpoint is the effect of treatment on the proportion of patients who require invasive mechanical ventilation and/or extracorporeal membrane oxygenation, or die by Day 28. An interim analysis will be conducted for futility after 154 patients have been enrolled. Safety will be assessed through 30 days of follow-up after the last dose of study treatment and assessed by the cumulative incidence, severity and seriousness of treatment-emergent AEs, drug discontinuations, laboratory values, and clinical assessments.

    Further information on the PRE-VENT study can be found at https://clinicaltrials.gov/ct2/show/NCT04404361?term=NCT04404361&draw=2&rank=1.

    About Pacritinib
    Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, IRAK1 and CSF1R. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia and lymphoma. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in inflammatory and immune-mediated disorders such acute graft-versus-host disease (aGVHD) and hemophagocytic lymphohistiocytosis (HLH).

    About CTI BioPharma Corp.
    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. We are headquartered in Seattle, Washington.

    Forward-Looking Statements
    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to conduct and complete clinical trials in our currently anticipated timeframes; our ability to successfully demonstrate the safety and efficacy of pacritinib; our expectations regarding the completion and outcome of the PACIFICA Phase 3 trial and the PRE-VENT Phase 3 trial; the risk that the FDA may determine that the benefit/risk profile of pacritinib at the dose selected for the PACIFICA Phase 3 trial does not support approval; the risk that the FDA may determine that the benefit/risk profile of pacritinib in the PRE-VENT Phase 3 trial does not support approval or requires additional clinical data for approval; the risk that pacritinib may fail in development; our ability to submit an NDA for pacritinib in the timeline currently anticipated; our ability to receive regulatory approval for pacritinib pursuant to the accelerated approval pathway or at all; the risk that pacritinib may be delayed to a point where it is not commercially viable; the accuracy of our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations; risks and uncertainties related to the COVID-19 pandemic as it relates to our operations and ongoing clinical trials; and those risks more fully discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

    "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:
    Maeve Conneighton/Maghan Meyers
    +212-600-1902
    cti@argotpartners.com

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-enrollment-of-first-patient-in-covid-19-pre-vent-phase-3-clinical-trial-301068348.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  43. SEATTLE, May 28, 2020 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ:CTIC) today announced that management will provide a corporate overview at the Jefferies 2020 Healthcare Conference at 2:30 p.m. EDT. The conference will be held in a virtual meeting format.

    Presentation details:


    Event:

    Jefferies 2020 Healthcare Conference    

    Date:

    Thursday, Jun. 4

    Time:  

    2:30 p.m. EDT

    The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit…

    SEATTLE, May 28, 2020 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ:CTIC) today announced that management will provide a corporate overview at the Jefferies 2020 Healthcare Conference at 2:30 p.m. EDT. The conference will be held in a virtual meeting format.

    Presentation details:


    Event:

    Jefferies 2020 Healthcare Conference    

    Date:

    Thursday, Jun. 4

    Time:  

    2:30 p.m. EDT

    The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Argot Partners
    Maeve Conneighton/Maghan Meyers  
    +1-212-600-1902
    CTI@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-jefferies-2020-healthcare-conference-on-thursday-jun-4-301066429.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  44. SEATTLE, May 7, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the first quarter ended March 31, 2020.

    "With a sufficient cash runway into Q4 2021, we have the resources to continue to advance pacritinib as quickly as possible as a potential treatment for severely thrombocytopenic myelofibrosis patients through the execution of the ongoing Phase 3 PACIFICA trial," said Adam R. Craig, M.D., Ph.D. "Additionally, in response to the global COVID-19 pandemic, as pacritinib has the potential to reduce the inflammatory response to the infection, which can lead to acute respiratory distress and mechanical ventilation, we recently announced the initiation of PRE-VENT, a Phase 3 double-blind, placebo-controlled…

    SEATTLE, May 7, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the first quarter ended March 31, 2020.

    "With a sufficient cash runway into Q4 2021, we have the resources to continue to advance pacritinib as quickly as possible as a potential treatment for severely thrombocytopenic myelofibrosis patients through the execution of the ongoing Phase 3 PACIFICA trial," said Adam R. Craig, M.D., Ph.D. "Additionally, in response to the global COVID-19 pandemic, as pacritinib has the potential to reduce the inflammatory response to the infection, which can lead to acute respiratory distress and mechanical ventilation, we recently announced the initiation of PRE-VENT, a Phase 3 double-blind, placebo-controlled, multicenter study of pacritinib for the treatment of hospitalized patients with severe COVID-19, including patients with and without cancer. We look forward to providing updates on the PRE-VENT trial in the coming months. With regards to the PACIFICA Phase 3 trial timeline, we anticipate at least a three-month delay to enrollment due to the COVID-19 pandemic."

    First Quarter Financial Results

    Operating loss was $11.9 million for the first quarter of 2020, compared to operating loss of $10.5 million for the same period in 2019. The increase in operating loss in the first quarter of 2020 as compared to operating loss in the same period in 2019 resulted primarily from expenses related to provisions for our Italian Value Added Tax receivables due to uncertainty regarding the collectability of such receivables as a result of the recent COVID-19 global pandemic, partially offset by decreases in research and development expenses and restructuring expenses.

    License and contract revenues for the three months ended March 31, 2019 were $0.6 million while no revenues were recognized for the same period in 2020. The decrease is primarily due to royalty and other revenues recognized in 2019 from Les Laboratoires Servier and Institut de Recherches Internationales Servier ("Servier") related to transition period activities pursuant to the terms of the Termination and Transfer Agreement with Servier.

    Net loss attributable to common stockholders for the first quarter of 2020 was $12.2 million, or $(0.20) for basic and diluted loss per share, compared to net loss attributable to common stockholders of $10.8 million, or $(0.19) for basic and diluted loss per share, for the same period in 2019.

    As of March 31, 2020, cash, cash equivalents and short-term investments totaled $81.1 million, compared to $33.7 million as of December 31, 2019. We expect current cash, cash equivalents and short-term investments will enable us to fund our operations into the fourth quarter of 2021.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. We are headquartered in Seattle, Washington.

    Forward-Looking Statements

    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to conduct and complete clinical trials in our currently anticipated timeframes; our ability to successfully demonstrate the safety and efficacy of pacritinib; our expectations regarding the completion and outcome of the PACIFICA Phase 3 trial and the PRE-VENT Phase 3 trial; the risk that the FDA may determine that the benefit/risk profile of pacritinib at the dose selected for the PACIFICA Phase 3 trial does not support approval; the risk that the FDA may determine that the benefit/risk profile of pacritinib in the PRE-VENT Phase 3 trial does not support approval or requires additional clinical data for approval; the risk that pacritinib may fail in development; our ability to submit an NDA for pacritinib in the timeline currently anticipated; our ability to receive regulatory approval for pacritinib pursuant to the accelerated approval pathway or at all; the risk that pacritinib may be delayed to a point where it is not commercially viable; the accuracy of our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations; risks and uncertainties related to the COVID-19 pandemic as it relates to our operations and ongoing clinical trials; and those risks more fully discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

    "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:
    Maeve Conneighton/Maghan Meyers
    +212-600-1902
    cti@argotpartners.com

    (tables follow)

     

    CTI BioPharma Corp.

    Condensed Consolidated Statements of Operations

    (In thousands, except per share amounts)

    (unaudited)


    Three Months Ended

     March 31,


    2020


    2019

    License and contract revenues

    $



    $

    640


    Operating costs and expenses:




    Research and development

    3,264



    5,172


    General and administrative

    4,467



    5,206


    Restructuring expenses



    794


    Other operating expenses

    4,200




    Total operating costs and expenses

    11,931



    11,172


    Loss from operations

    (11,931)



    (10,532)


    Non-operating income (expense):




    Interest income

    119



    380


    Interest expense

    (167)



    (294)


    Amortization of debt discount and issuance costs

    (130)



    (130)


    Foreign exchange loss

    (77)



    (238)


    Total non-operating expense, net

    (255)



    (282)


    Net loss

    $

    (12,186)



    $

    (10,814)


    Basic and diluted net loss per common share

    $

    (0.20)



    $

    (0.19)


    Shares used in calculation of basic and diluted net loss per common share:

    62,461



    57,973


     

    Balance Sheet Data (unaudited):


    (amounts in thousands)



    March 31,


    December 31,



    2020


    2019

    Cash and cash equivalents


    $

    81,149



    $

    31,144


    Short-term investments




    2,522


    Working capital


    68,234



    17,092


    Total assets


    87,981



    46,280


    Current portion of long-term debt


    4,812



    4,812


    Long-term debt, less current portion


    3,252



    4,455


    Total stockholders' equity


    22,384



    17,930


     

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-reports-first-quarter-2020-financial-results-301055212.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  45. SEATTLE, April 27, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced the initiation of PRE-VENT, a Phase 3 study evaluating pacritinib in hospitalized patients with severe COVID-19. PRE-VENT, a randomized, double-blind, placebo-controlled multicenter study, will compare pacritinib plus standard of care (SOC) versus placebo plus standard of care in 358 hospitalized patients with severe COVID-19, including patients with and without cancer. The primary endpoint of the trial will assess the proportion of patients who progress to invasive mechanical ventilation and/or extracorporeal membrane oxygenation or die by Day 28. CTI expects to commence enrollment of PRE-VENT in May at sites in the United States and in Europe with data…

    SEATTLE, April 27, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced the initiation of PRE-VENT, a Phase 3 study evaluating pacritinib in hospitalized patients with severe COVID-19. PRE-VENT, a randomized, double-blind, placebo-controlled multicenter study, will compare pacritinib plus standard of care (SOC) versus placebo plus standard of care in 358 hospitalized patients with severe COVID-19, including patients with and without cancer. The primary endpoint of the trial will assess the proportion of patients who progress to invasive mechanical ventilation and/or extracorporeal membrane oxygenation or die by Day 28. CTI expects to commence enrollment of PRE-VENT in May at sites in the United States and in Europe with data expected by the end of 2020.

    "Patients with severe COVID-19, particularly those with cancer, are at high risk for serious complications from the disease stemming from cytokine storm, an inflammatory response that causes white blood cells to not only fight the viral infection, but also damage tissue, primarily in the lungs," said John Mascarenhas, M.D., Associate Professor, Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York and Chief Investigator of the PRE-VENT Study. "Because pacritinib inhibits JAK2, IRAK-1 and CSF1R, there is real potential for pacritinib to prevent patients from developing an inflammatory response to the coronavirus infection and subsequent pulmonary failure, therefore reducing the need for a ventilator."

    "Given the unprecedented medical need to improve outcomes for patients with COVID-19, we have made a commitment to test pacritinib, a JAK2/IRAK-1/CSF-1R inhibitor, in hospitalized patients with severe COVID-19, with the goal of preventing progression to acute respiratory distress syndrome and mechanical ventilation," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI Biopharma. "Emerging evidence suggests that the attenuation of the cytokine storm associated with COVID-19 could be a potential treatment approach for this devastating disease, and it is hypothesized that pacritinib may have a role in treating these patients. We would like to thank the FDA for their expedited review of the PRE-VENT protocol. Enrollment is expected to commence in the coming weeks. With ample supply of pacritinib available, we continue to recruit patients on the pivotal Phase 3 PACIFICA trial of pacrtitnib in myelofibrosis patients with severe thrombocytopenia."

    Cytokine storm is a pathological immune reaction that can be triggered by viral infection and can lead to serious complications, including acute respiratory distress syndrome (ARDS). Multiple inflammatory cytokines are upregulated in patients with severe COVID-19, including IL-1 and IL-6, and some patients have evidence of over-active macrophage activation. As a JAK2/IRAK-1 inhibitor, pacritinib may ameliorate the effects of cytokine storm via inhibition of IL-6 and IL-1 signaling. Furthermore, as a CSF-1R inhibitor, pacritinib may mitigate effects of macrophage activation syndrome. Of particular importance in this indication, pacritinib has not been associated with increased risk in infections in prior randomized studies, likely because it does not have inhibitory effects on JAK1. 

    About PRE-VENT
    PRE-VENT is expected to enroll 358 patients randomized 1:1 to receive pacritinib (400 mg once daily on Day 1, then 200 mg twice daily from Day 2 to Day 14) + SOC or placebo + SOC. Assigned treatment will continue for up to Day 14 or until the patient experiences intolerable adverse events, withdraws consent, initiates another investigational therapy, or until the study is terminated. Assigned therapy may be given for an additional 7 days (for a total of 21 days) at the discretion of the investigator. In the event of hospital discharge, patients will complete treatment with the assigned therapy as an outpatient. Severe COVID-19 will be defined as an oxygen saturation (SO2) ≤93% on room air at sea level, respiratory frequency >30 breaths per minute, ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300, or lung infiltrates >50% on radiographic imaging.

    The primary endpoint is the effect of treatment on the proportion of patients who require invasive mechanical ventilation and/or extracorporeal membrane oxygenation, or die by Day 28. An interim analysis will be conducted for futility after 154 patients have been enrolled. Safety will be assessed through 30 days of follow-up after the last dose of study treatment and assessed by the cumulative incidence, severity and seriousness of treatment-emergent AEs, drug discontinuations, laboratory values, and clinical assessments.

    About Pacritinib
    Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, IRAK1 and CSF1R. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia and lymphoma. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in inflammatory and immune-mediated disorders such acute graft-versus-host disease (aGVHD) and hemophagocytic lymphohistiocytosis (HLH).

    About CTI BioPharma Corp.
    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. We are headquartered in Seattle, Washington.

    Forward-Looking Statements
    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to conduct and complete clinical trials in our currently anticipated timeframes; our ability to successfully demonstrate the safety and efficacy of pacritinib, including in COVID-19 patients; our expectations regarding the completion and outcome of the PACIFICA Phase 3 trial and the PRE-VENT Phase 3 trial; the risk that the FDA may determine that the benefit/risk profile of pacritinib at the dose selected for the PACIFICA Phase 3 trial does not support approval; the risk that the FDA may determine that the benefit/risk profile of pacritinib in the PRE-VENT Phase 3 trial does not support approval or requires additional clinical data for approval; the risk that pacritinib may fail in development; our ability to submit an NDA for pacritinib in the timeline currently anticipated; our ability to receive regulatory approval for pacritinib pursuant to the accelerated approval pathway or at all; the risk that pacritinib may be delayed to a point where it is not commercially viable; the accuracy of our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations; riks and uncertainties related to the COVID-19 pandemic as it relates to our operations and ongoing clinical trials; and those risks more fully discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2019. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

    "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:
    Maeve Conneighton/Maghan Meyers
    +212-600-1902
    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-initiation-of-phase-3-pre-vent-study-evaluating-pacritinib-in-hospitalized-patients-with-severe-covid-19-301047305.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  46. SEATTLE, April 8, 2020 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ:CTIC) today announced that management will provide a corporate overview at the Needham Healthcare Conference at 10:40 a.m. EDT. The conference will be held in a virtual meeting format.

    Presentation details:



    Event:       

    Needham Healthcare Conference   

    Date:         

    Wednesday, Apr. 15

    Time:        

    10:40 a.m. EDT

    The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to…

    SEATTLE, April 8, 2020 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ:CTIC) today announced that management will provide a corporate overview at the Needham Healthcare Conference at 10:40 a.m. EDT. The conference will be held in a virtual meeting format.

    Presentation details:





    Event:       

    Needham Healthcare Conference   

    Date:         

    Wednesday, Apr. 15

    Time:        

    10:40 a.m. EDT

    The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

    About CTI BioPharma Corp.

    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. We are headquartered in Seattle, Washington.

    CTI BioPharma Investor Contacts:

    Argot Partners

    Maeve Conneighton/Maghan Meyers  

    +1-212-600-1902

    CTI@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-needham-healthcare-conference-on-wednesday-apr-15-301037177.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  47. SEATTLE, March 12, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the fourth quarter and full year ended December 31, 2019.

    "In the latter half of 2019 and beginning of 2020, we further advanced our pacritinib development program, including presenting data at the American Society of Hematology Annual Meeting that reinforced the clinical and scientific rationale for our ongoing PAC203 Phase 3 PACIFICA trial evaluating pacritinib at 200 mg BID in severely thrombocytopenic myelofibrosis patients," said Adam R. Craig, M.D., Ph.D. "Severely thrombocytopenic myelofibrosis patients have limited, and often ineffective, therapeutic options. In an effort to advance pacritinib as quickly as possible to these…

    SEATTLE, March 12, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the fourth quarter and full year ended December 31, 2019.

    "In the latter half of 2019 and beginning of 2020, we further advanced our pacritinib development program, including presenting data at the American Society of Hematology Annual Meeting that reinforced the clinical and scientific rationale for our ongoing PAC203 Phase 3 PACIFICA trial evaluating pacritinib at 200 mg BID in severely thrombocytopenic myelofibrosis patients," said Adam R. Craig, M.D., Ph.D. "Severely thrombocytopenic myelofibrosis patients have limited, and often ineffective, therapeutic options. In an effort to advance pacritinib as quickly as possible to these patients, we established an accelerated approval pathway with the U.S. Food and Drug Administration ("FDA") by amending the PACIFICA pivotal Phase 3 trial protocol to allow for the primary analysis of Spleen Volume Reduction ("SVR") rates on the first 168 patients, with an end-of-study analysis of Total Symptom Score ("TSS") and Overall Survival ("OS") following the full enrollment of 348 patients. If the primary endpoint of SVR is met following the planned review of data from the first 168 patients, we intend to submit a New Drug Application ("NDA") under the FDA's subpart H regulations. We expect to report primary SVR data by the end of 2021, with a potential NDA filing in early 2022. Additionally, we recently raised an additional $59.3 million in a rights offering, which provides us with additional cash runway into Q1 2022 as we continue to develop pacritinib."

    Fourth Quarter Financial Results
    Operating loss was $9.5 million and $40.7 million for the three months and year ended December 31, 2019, respectively, compared to operating income of $0.2 million and operating loss of $32.9 million for the respective periods in 2018. The operating loss during the three-month period ended December 31, 2019 as compared to the operating income for the comparable period in 2018 resulted primarily from the decrease in license and contract revenue as discussed below, partially offset by a decrease in operating expenses. The increase in operating loss for the year ended December 31, 2019 as compared to the same period in 2018 resulted primarily from a decrease in license and contract revenues between periods as discussed below, partially offset by a decrease in operating expenses. As of December 31, 2019, cash, cash equivalents and short-term investments totaled $33.7 million, compared to $67.0 million as of December 31, 2018. In March 2020, we completed our rights offering and received approximately $59.3 million in net proceeds. We expect current cash, cash equivalents and short-term investments, when combined with the net proceeds we received from the rights offering, will enable us to fund our operations into the first quarter of 2022.

    License and contract revenues for the three months ended December 31, 2018 were $14.1 million while no revenues were recognized during the three months ended December 31, 2019. License and contract revenues for the three months ended December 31, 2018 were primarily related to milestone revenues recognized upon the achievement of a regulatory milestone under the license and collaboration agreement for PIXUVRI® with Les Laboratoires Servier and Institut de Recherches Internationales Servier as well as the attainment of a worldwide net sales milestone of TRISENOX® (arsenic trioxide) under the agreement with Teva Pharmaceutical Industries Ltd. ("Teva"). License and contract revenues for the years ended December 31, 2019 and 2018 were $3.3 million and $26.3 million, respectively. The decrease between periods primarily resulted from milestone revenues recognized in 2018 from Teva related to the achievement of a milestone for FDA approval of TRISENOX for first-line treatment of acute promyelocytic leukemia, in addition to the license and contract revenues recognized during the three months ended December 31, 2018, as discussed above.

    Net loss attributable to common stockholders for the three months ended December 31, 2019 was $8.2 million, or $(0.14) for basic and diluted loss per share, compared to net income attributable to common stockholders of $0.8 million, or $0.01 for basic and diluted income per share, for the same period in 2018. Net loss attributable to common stockholders for the year ended December 31, 2019 was $40.0 million, or $(0.69) for basic and diluted loss per share, compared to net loss attributable to common stockholders of $29.4 million, or $(0.52) for basic and diluted loss per share, for the same period in 2018.

    About CTI BioPharma Corp.
    We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. We are headquartered in Seattle, Washington.

    Forward-Looking Statements
    Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to conduct and complete clinical trials in our currently anticipated timeframes; our ability to successfully demonstrate the safety and efficacy of pacritinib; our expectations regarding the completion and outcome of the PACIFICA Phase 3 trial; the risk that the FDA may determine that the benefit/risk profile of pacritinib at the dose selected for the PACIFICA Phase 3 trial does not support approval; the risk that pacritinib may fail in development; our ability to submit an NDA for pacritinib in the timeline currently anticipated; our ability to receive regulatory approval for pacritinib pursuant to the accelerated approval pathway or at all; the risk that pacritinib may be delayed to a point where it is not commercially viable; the accuracy of our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations; and those risks more fully discussed in the section entitled "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

    "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:
    Maeve Conneighton/Maghan Meyers
    +212-600-1902
    cti@argotpartners.com

    (tables follow)

    CTI BioPharma Corp.

    Condensed Consolidated Statements of Operations

    (In thousands, except per share amounts)

    (unaudited)



    Three Months Ended

     December 31,


    Twelve Months Ended

     December 31,


    2019


    2018


    2019


    2018

    License and contract revenues

    $



    $

    14,108



    $

    3,345



    $

    26,290


    Operating costs and expenses:








    Research and development

    4,981



    7,928



    24,107



    36,467


    Selling, general and administrative

    4,493



    5,312



    19,155



    22,062


    Restructuring expenses



    660



    794



    660


    Total operating costs and expenses

    9,474



    13,900



    44,056



    59,189


    (Loss) income from operations

    (9,474)



    208



    (40,711)



    (32,899)


    Non-operating income (expense):








    Interest income

    169



    419



    1,172



    1,219


    Interest expense

    (199)



    (316)



    (1,002)



    (1,209)


    Amortization of debt discount and issuance costs

    (130)



    (131)



    (521)



    (525)


    Foreign exchange gain (loss)

    128



    665



    (281)



    (233)


    Other non-operating income

    1,320





    1,320



    4,295


    Total non-operating income, net

    1,288



    637



    688



    3,547


    Net (loss) income before noncontrolling interest

    (8,186)



    845



    (40,023)



    (29,352)


    Noncontrolling interest

    (2)



    1



    3



    32


    Net (loss) income

    (8,188)



    846



    (40,020)



    (29,320)


    Deemed dividends on preferred stock







    (80)


    Net (loss) income attributable to common stockholders

    $

    (8,188)



    $

    846



    $

    (40,020)



    $

    (29,400)


    Net (loss) income per common share:








        Basic

    $

    (0.14)



    $

    0.01



    $

    (0.69)



    $

    (0.52)


        Diluted

    $

    (0.14)



    $

    0.01



    $

    (0.69)



    $

    (0.52)


    Shares used in calculation of (loss) income per common share:








        Basic

    57,974



    57,969



    57,974



    56,073


        Diluted

    57,974



    57,970



    57,974



    56,073


     

    Balance Sheet Data (unaudited):


    (amounts in thousands)



    December 31,


    December 31,



    2019


    2018

    Cash and cash equivalents


    $

    31,144



    $

    36,439


    Short-term investments


    2,522



    30,599


    Working capital


    17,092



    59,437


    Total assets


    46,280



    89,832


    Current portion of long-term debt


    4,812



    4,812


    Long-term debt, less current portion


    4,455



    9,267


    Total stockholders' equity


    17,930



    52,939


     

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-reports-fourth-quarter-and-full-year-2019-financial-results-301022480.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  48. SEATTLE, March 6, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced the closing of its previously announced rights offering (the "Rights Offering").  At the closing, CTI BioPharma sold and issued an aggregate of 15,698,995 shares of its common stock (the "Common Stock") and an aggregate of 4,429.2423 shares of its series X convertible preferred stock (the "Series X Preferred") pursuant to the exercise of subscription rights and Oversubscription Rights in the Rights Offering by existing holders of CTI Biopharma's Common Stock and series O convertible preferred stock. The Rights Offering was fully backstopped by certain existing stockholders of CTI BioPharma who agreed to purchase any shares of Common Stock and/or Series X…

    SEATTLE, March 6, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced the closing of its previously announced rights offering (the "Rights Offering").  At the closing, CTI BioPharma sold and issued an aggregate of 15,698,995 shares of its common stock (the "Common Stock") and an aggregate of 4,429.2423 shares of its series X convertible preferred stock (the "Series X Preferred") pursuant to the exercise of subscription rights and Oversubscription Rights in the Rights Offering by existing holders of CTI Biopharma's Common Stock and series O convertible preferred stock. The Rights Offering was fully backstopped by certain existing stockholders of CTI BioPharma who agreed to purchase any shares of Common Stock and/or Series X Preferred offered in the Rights Offering that were not subscribed for (the "Oversubscription Rights"). CTI BioPharma raised aggregate gross proceeds of approximately $60.0 million in the Rights Offering.

    Of the total shares of Common Stock and Series X Preferred sold and issued in the Rights Offering, certain affiliates of BVF Partners L.P. purchased 3,047 shares of Series X Preferred, Stonepine Capital, LP purchased 3,267,127 shares of Common Stock and 673.2873 shares of Series X Preferred, OrbiMed Private Investments VI, LP purchased 4,520,600 shares of Common Stock and 298 shares of Series X Preferred and New Enterprise Associates, Inc. purchased 3,390,450 shares of Common Stock and 410.955 shares of Series X Preferred, in each case, pursuant to the exercise of their subscription rights and Oversubscription Rights.

    The Rights Offering was made pursuant to CTI BioPharma's effective shelf registration statement on file with the Securities and Exchange Commission (the "SEC") and a prospectus supplement and accompanying prospectus filed with the SEC on February 14, 2020.

    JMP Securities served as financial advisor to CTI BioPharma in connection with the Rights Offering.

    About CTI BioPharma Corp.

    CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. In particular, CTI BioPharma is focused on evaluating pacritinib for the treatment of adult patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington.

    "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:
    Maeve Conneighton/Maghan Meyers
    +212-600-1902
    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-closing-of-rights-offering-301019300.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  49. SEATTLE, Feb. 14, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today commenced its previously announced rights offering to raise gross proceeds of approximately $60.0 million (the "Rights Offering"). Under the terms of the Rights Offering, the holders, as of 5:00 p.m., New York time, on February 13, 2020, of CTI BioPharma's common stock (the "Common Stock") and series O convertible preferred stock (the "Series O Preferred"), are entitled to exercise their subscription rights to purchase their pro rata share (assuming full conversion of the Series O Preferred into shares of Common Stock) of the $60.0 million offering amount, as more fully described in the prospectus supplement (and accompanying prospectus), dated February 14, 2020

    SEATTLE, Feb. 14, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today commenced its previously announced rights offering to raise gross proceeds of approximately $60.0 million (the "Rights Offering"). Under the terms of the Rights Offering, the holders, as of 5:00 p.m., New York time, on February 13, 2020, of CTI BioPharma's common stock (the "Common Stock") and series O convertible preferred stock (the "Series O Preferred"), are entitled to exercise their subscription rights to purchase their pro rata share (assuming full conversion of the Series O Preferred into shares of Common Stock) of the $60.0 million offering amount, as more fully described in the prospectus supplement (and accompanying prospectus), dated February 14, 2020, relating to the Rights Offering (the "Prospectus"). Each subscription right may be exercised to purchase a share of Common Stock at a subscription price equal to $1.00 per share of Common Stock or, in lieu of Common Stock, an equivalent number of shares of non-voting series X convertible preferred stock (the "Series X Preferred") at a purchase price equal to $10,000 per share of Series X Preferred. The subscription rights may be exercised at any time during the subscription period of February 14, 2020 through 5:00 p.m., New York time, on March 2, 2020.

    The Rights Offering will be fully backstopped by BVF Partners L.P., Stonepine Capital, L.P., OrbiMed Private Investments VI, LP and New Enterprise Associates, Inc. (the "Backstop Investors") each of which have agreed to purchase its respective as-converted pro rata share of the offering amount, plus an additional amount of Common Stock or Series X Preferred that are not subscribed for by other purchasers in the Rights Offering, for a total of up to $60.0 million.

    CTI BioPharma reserves the right to modify, extend, postpone or cancel the Rights Offering at any time prior to the closing of the sale of the securities offered in the Rights Offering. CTI BioPharma has engaged Georgeson LLC to act as information agent with respect to the Rights Offering. For questions regarding the Rights Offering, or to obtain copies of the Prospectus and any related materials, please contact Georgeson LLC by telephone at 888-613-9988.

    CTI BioPharma has filed a shelf registration statement (including a prospectus supplement) with the Securities and Exchange Commission (the "SEC").  Before you invest, you should read the Prospectus and the other documents CTI BioPharma has filed with the SEC for more complete information about CTI BioPharma and the Rights Offering. This press release is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

    About CTI BioPharma Corp.
    CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. In particular, we are focused on evaluating pacritinib for the treatment of adult patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington.

    Forward-Looking Statements
    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding our expectations regarding plans, amounts and timing for the Rights Offering, the purchase of unsubscribed securities by the Backstop Investors and expectations regarding participation in the Rights Offering.

    Risks Related to Forward-Looking Statements
    The forward-looking statements contained in this press release are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to risks identified in our filings with the SEC. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

    "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:
    Maeve Conneighton/Maghan Meyers
    +212-600-1902
    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-commencement-of-rights-offering-301004948.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  50. SEATTLE, Feb. 3, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced its intent to raise $60 million through a fully backstopped rights offering. Under the terms of the rights offering, investors as of February 13, 2020 in CTI BioPharma's common stock and preferred stock will receive a subscription right entitling them to purchase their pro rata share of the $60 million offering amount. The rights offering will be fully backstopped by BVF Partners L.P., Stonepine Capital, L.P., OrbiMed Private Investments VI, LP and New Enterprise Associates, Inc. each of which have agreed to purchase, at a minimum, its respective as-converted pro rata share of the offering amount, plus an additional amount of securities that are not subscribed…

    SEATTLE, Feb. 3, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced its intent to raise $60 million through a fully backstopped rights offering. Under the terms of the rights offering, investors as of February 13, 2020 in CTI BioPharma's common stock and preferred stock will receive a subscription right entitling them to purchase their pro rata share of the $60 million offering amount. The rights offering will be fully backstopped by BVF Partners L.P., Stonepine Capital, L.P., OrbiMed Private Investments VI, LP and New Enterprise Associates, Inc. each of which have agreed to purchase, at a minimum, its respective as-converted pro rata share of the offering amount, plus an additional amount of securities that are not subscribed for by other purchasers in the rights offering, for a total of up to $60 million.

    Under the proposed rights offering (the "Rights Offering"), CTI BioPharma plans to distribute non-transferable subscription rights to purchase a portion of a share of CTI BioPharma's common stock ("Common Stock") or series X convertible preferred stock ("Series X Preferred") to each stockholder of record of Common Stock, including Common Stock issuable upon conversion of the outstanding shares of CTI Biopharma's series O convertible preferred stock ("Series O Preferred") at $1.00 per share to such security holders of record as of the close of business on February 13, 2020 (the "Record Date"). The subscription rights will be exercisable for shares of Common Stock (or an equivalent number of Series X Preferred), with participation to be allocated among holders of its Common Stock and Series O Preferred on a pro rata basis (assuming full conversion of the Series O Preferred into shares of Common Stock), subject to the aggregate offering threshold and ownership limitations. The subscription rights may be exercised only during the anticipated subscription period of Friday, February 14, 2020, through 5:00 PM (Eastern Time) on Monday, March 2, 2020, unless extended. Any participant in the Rights Offering that, by exercise of its subscription right would become a holder of greater than 9.9% of the outstanding number of shares of Common Stock following the Rights Offering may elect to instead purchase Series X Preferred. CTI BioPharma intends to sell the Series X Preferred at $10,000 per share, and any such holder so electing would have a right to purchase one 10,000th of a share of Series X Preferred for each share of Common Stock it had a right to purchase under the subscription rights. Each share of Series X Preferred is, subject to certain limitations, convertible into 10,000 shares of Common Stock at the election of the holder. The Series X Preferred generally have no voting rights, except as required by law, and will participate pari passu, on an as-converted basis, with any distribution of proceeds to holders of Common Stock and Series O Preferred in the event of CTI BioPharma's liquidation, dissolution or winding up.

    The Rights Offering will be made pursuant to CTI BioPharma's effective shelf registration statement on file with the Securities and Exchange Commission and only by means of a prospectus supplement and accompanying prospectus. CTI BioPharma expects to mail subscription certificates evidencing the subscription rights and a copy of the prospectus supplement and accompanying prospectus for the Rights Offering shortly following the Record Date.

    This press release is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

    Certain existing shareholders of CTI BioPharma (the "Investors"), including BVF Partners L.P., CTI BioPharma's largest shareholder, currently owning approximately 11.95% of CTI BioPharma's outstanding Common Stock (and 23.1% on an as-converted basis), Stonepine Capital, L.P., OrbiMed Private Investments VI, LP and New Enterprise Associates, Inc. currently owning 6.23%, 8.62% and 5.59% of CTI BioPharma's outstanding Common Stock, respectively, will backstop the Rights Offering and have agreed to purchase up to $60 million of Common Stock at a subscription price per share of $1.00 (or Series X Preferred at a price of $10,000 per share) in a private placement promptly at the conclusion of the Rights Offering, with the dollar amount to be purchased in such private placement reduced by the dollar amount sold by CTI BioPharma (including to the Investors and their respective affiliates) in the Rights Offering.

    Concurrent with this press release, CTI is announcing the outcome of its recent meeting with the U.S. Food and Drug Administration and the subsequent amendment to the PACIFICA trial. For further details, see the concurrent press release relating to this meeting.

    About CTI BioPharma Corp.
    CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. In particular, we are focused on evaluating pacritinib for the treatment of adult patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington.

    Forward-Looking Statements
    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding our expectations regarding plans, amounts and timing for the Rights Offering and the private placement to the Investors, future financing opportunities, the anticipated use of proceeds derived therefrom and expectations regarding participation in the Rights Offering.

    Risks Related to Forward-Looking Statements
    The forward-looking statements contained in this press release are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

    "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:
    Maeve Conneighton/Maghan Meyers
    +212-600-1902
    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-proposed-rights-offering-300997420.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  51. SEATTLE, Feb. 3, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that following a meeting with the U.S. Food and Drug Administration ("FDA" or "the Agency"), CTI has reached agreement on an accelerated approval pathway for pacritinib for the treatment of myelofibrosis patients with severe thrombocytopenia (platelet counts <50,000/µL).  CTI will be amending the PACIFICA pivotal Phase 3 trial protocol to allow for the primary analysis of SVR rates on the first 168 patients, with an end-of-study analysis of TSS and OS following the full enrollment of 348 patients. If the primary endpoint of SVR is met following the planned review of data from the first 168 patients, CTI intends to submit a New Drug Application (NDA) under the FDA's subpart H regulations, subject to review of all available efficacy and safety data. Conversion to a regular approval of pacritinib would be anticipated following the successful end-of-study assessment of the secondary efficacy endpoints, and the completion of post-marketing requirements.

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

    "Since the initiation of the PACIFICA trial in September 2019, we have been working diligently with the FDA to identify an expedited approval pathway for pacritinib for the treatment of myelofibrosis patients with severe thrombocytopenia," said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI Biopharma. "Severely thrombocytopenic myelofibrosis patients (platelet counts <50,000/µL) have reduced survival and very limited therapeutic options. Pacritinib has now demonstrated clinical benefit in this population in three clinical trials, including two prior randomized Phase 3 studies, so we believe that pacritinib has the potential to change the treatment paradigm in this area of serious unmet medical need."

    Based on the new trial design, CTI expects to report primary SVR data by the end of 2021, with a potential NDA filing in early 2022 if the SVR data is positive. Final study efficacy data is expected in 2023.

    Concurrent with this press release, CTI is announcing a $60 million rights offering. For further details, see the concurrent press release relating to the rights offering.

    About Myelofibrosis and Severe Thrombocytopenia
    Myelofibrosis is a type of bone marrow cancer that results in formation of fibrous scar tissue and can lead to severe anemia, weakness, fatigue and an enlarged spleen and liver. Patients with severe thrombocytopenia are estimated to make up more than one-third of patients treated for myelofibrosis, or approximately 17,000 people. Severe thrombocytopenia, defined as blood platelet counts of less than 50,000 per microliter, has been shown to result in overall survival rates of just 15 months. Thrombocytopenia in patients with myelofibrosis is associated with the underlying disease but has also been shown to correlate with treatment with ruxolitinib, which can lead to dose reductions, and as a result, may potentially reduce clinical benefit. Survival in patients who have discontinued ruxolitinib therapy is further compromised, with an average overall survival of seven to 14 months. There are currently no approved therapies available to treat myelofibrosis patients with severe thrombocytopenia or patients who have failed ruxolitinib treatment, thereby making this a significant unmet medical need.

    About Pacritinib
    Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia and lymphoma. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and chronic lymphocytic leukemia (CLL), due to its inhibition of c-fms, IRAK1, JAK2 and FLT3.

    About CTI BioPharma Corp.
    CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. In particular, we are focused on evaluating pacritinib for the treatment of adult patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington.

    Forward-Looking Statements
    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding our expectations regarding: the anticipated trial design of the PACIFICA Phase 3 trial, including changes to the protocol as discussed in this press release; the anticipated enrollment of the PACIFICA Phase 3 trial; the effectiveness of, and potential changes to, the PACIFICA Phase 3 trial design; the timing of, and results from, clinical trials and other development activities related to pacritinib, including the PACIFICA Phase 3 trial and its related protocol; the potential efficacy, safety profile, future development plans, addressable market, regulatory success and commercial potential of pacritinib; the anticipated timing of regulatory submissions and interactions, including any potential NDA submission; our ability to expedite the regulatory approval process; our ability to successfully develop and achieve milestones in the development of pacritinib; and the anticipated benefits of pacritinib.

    Risks Related to Forward-Looking Statements
    The forward-looking statements contained in this press release are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: clinical trials may not demonstrate safety and efficacy of pacritinib; the FDA may determine that the benefit/risk profile of pacritinib at the dose selected for the PACIFICA Phase 3 trial does not support approval based on the results of such trial, previously identified FDA concerns regarding safety and dosing limitations or otherwise; pacritinib may fail in development, may not receive required regulatory approvals, or may be delayed to a point where it is not commercially viable; our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations may be incorrect; we may not achieve additional milestones in our pacritinib development program; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

    "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:
    Maeve Conneighton/Maghan Meyers
    +212-600-1902
    cti@argotpartners.com

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-establishes-accelerated-approval-pathway-for-pacritinib-in-treating-myelofibrosis-patients-with-severe-thrombocytopenia-300997421.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  52. SEATTLE, Dec. 9, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced the presentation of data from the Company's pacritinib development program, including results from the PAC203 Phase 2 clinical trial, at the 61st American Society of Hematology (ASH) Annual Meeting being held December 7-10 in Orlando, Florida.

    "The data presented at ASH underscore the clinical and scientific rationale for our ongoing PAC203 Phase 3 PACIFICA trial evaluating pacritinib at 200 mg BID in severely thrombocytopenic myelofibrosis patients," said Adam R. Craig, M.D., Ph.D. "Pacritinib has now been demonstrated to provide clinical benefit in treating severely thrombocytopenic myelofibrosis (platelet counts less than 50,000 per microliter) in three

    SEATTLE, Dec. 9, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced the presentation of data from the Company's pacritinib development program, including results from the PAC203 Phase 2 clinical trial, at the 61st American Society of Hematology (ASH) Annual Meeting being held December 7-10 in Orlando, Florida.

    "The data presented at ASH underscore the clinical and scientific rationale for our ongoing PAC203 Phase 3 PACIFICA trial evaluating pacritinib at 200 mg BID in severely thrombocytopenic myelofibrosis patients," said Adam R. Craig, M.D., Ph.D. "Pacritinib has now been demonstrated to provide clinical benefit in treating severely thrombocytopenic myelofibrosis (platelet counts less than 50,000 per microliter) in three clinical trials, including two prior randomized Phase 3 studies. Further, the PAC203 Phase 2 results from the 200 mg BID cohort demonstrate a favorable risk-benefit profile for pacritinib when treating patients with advanced disease that have high mutational risk and long durations of prior ruxolitinib exposure. The totality of the data presented at ASH reinforces our belief that pacritinib has the potential to be an important therapy for severely thrombocytopenic myelofibrosis patients, a population for whom available therapeutic options are limited and often ineffective."

    "While currently available treatments for myelofibrosis convey clinical benefit to a majority of the population, patients who are severely thrombocytopenic, and are therefore considered high-risk, continue to lack safe and efficacious therapies," said Claire N. Harrison, M.D., Consultant Haematologist and Professor of Myeloproliferative Neoplasms in London, as well as Chair of the PACIFICA steering committee and Principal Investigator of the PAC203 Phase 2 trial. "Myelofibrosis patients with platelet counts of less than 50,000 per microliter have a median survival of approximately 8 months after discontinuation of first line ruxolitinib therapy. In the PAC203 Phase 2 trial, which represents one of the most advanced and heavily pre-treated myelofibrosis patient populations studied to date as demonstrated by a median prior exposure to ruxolitinib of 1.7 years and the high risk mutational profiles, pacritinib at 200 mg BID achieved an impressive response rate in the severely thrombocytopenic patient population of 17% with a promising safety profile, demonstrating its potential to change the treatment paradigm in this area of serious unmet medical need."  

    All posters and presentation materials will be available at ctibiopharma.com following the presentations.

    Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib

    Results from the PAC203 Phase 2 trial are being presented today, Monday, December 9, at 10:30 AM ET, in an oral presentation session.

    Abstract: No. 667

    Summary: PAC203 enrolled patients with myelofibrosis who were intolerant of or who had not benefitted from prior treatment with ruxolitinib. Patients were randomized in equal measure across 3 dosing arms: 200mg twice-daily (BID), 100mg BID, and 100mg daily (QD), with randomization stratified by baseline platelet count. Patients were mostly thrombocytopenic and anemic at baseline, with a median platelet count was 55,000, and 44% of patients having baseline platelet counts of less than 50,000. Patients had been heavily pre-treated with ruxolitinib, with a median 1.7 years of prior exposure. The study endpoint was broadly defined as an analysis of safety and efficacy data across dosing arms based on data after all patients either reached week 24 or stopped study treatment.

    Pacritinib was shown to be generally well tolerated across dosing cohorts, with the most common treatment-emergent non-hematologic adverse events (AEs) being gastrointestinal, including diarrhea (20.5%; Grade 3: 3.1%) and nausea (20%; Grade 3: 0.6%), distributed similarly across arms. The most common hematologic AEs were thrombocytopenia and anemia, both occurring at higher frequencies at the 200 mg dose BID (32% and 22% respectively); this did not, however, lead to higher rates of Grade 3/4 hemorrhage at higher doses (200 mg BID: 5.6%; 100 mg BID: 0%; 100 mg QD: 5.8%; all Grade 3). Similarly, the highest dose saw no excess in Grade 3/4 cardiac (200 mg BID: 3.7%; 100 mg BID: 7.3%; 100 mg QD: 3.7%; all Grade 3) or infectious (200 mg BID: 15%; 100 mg BID: 11%; 100 mg QD: 12%) AEs. In this cohort of advanced MF patients, there were 7 Grade 5 (fatal) AEs: 2 at 200 mg BID (sepsis, subdural hematoma), 3 at 100 mg BID (disease progression, subdural hematoma, heart failure), and 2 at 100 mg QD (sepsis, tuberculosis).

    The 200 mg BID arm had the highest observed rates of SVR ≥35% (200 mg BID: 9.3%; 100 mg BID: 1.8%; 100 mg QD: 0.0%). Of the 5 patients with SVR ≥35% at the 200 mg BID dose, 4 had platelet counts <50,000/mL, representing a 17% (4/24) response rate among patients with severe thrombocytopenia. Though a dose response relationship was not observed in total symptom score (TSS) based on the threshold of 50% reduction in symptom score, as 4 patients achieved this endpoint on all arms, the median reduction in TSS was greatest for patients treated at 200 mg BID (200 mg BID: 27%%; 100 mg BID: 16%; 100 mg QD: 3%).

    The data from PAC203 support the Phase 3 PACIFICA trial, currently underway to compare the safety and efficacy of 200 mg BID of pacritinib to Physician's Choice in 180 adult myelofibrosis patients with severe thrombocytopenia (platelet counts of less than 50,000 per microliter).

    The Oral JAK2/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2V617F Allele Burden

    Results from a retrospective analysis from two Phase 3 studies, PERSIST-1 and PERSIST-2, of pacritinib in myelofibrosis patients were presented in a poster session on Saturday, December 7.

    Abstract: No. 1674

    Summary: A retrospective analysis of PERSIST-1 and PERSIST-2 was performed in which outcomes were stratified by JAK2 V617F mutation status and allele burden. The efficacy endpoint for this study was the percentage of patients achieving ≥35% SVR at week 24 based on an intention-to-treat analysis. Analysis was based on pooled results across the two studies for patients treated with pacritinib and those treated with best available therapy (BAT), and assessed patients with JAK2 V617F for possible relationship between allelic burden and SVR at 24 weeks. The analysis showed pacritinib was associated with a significantly higher rate of SVR response than BAT among patients with low JAK2 allele burden (<50%), while no SVR response was observed for patients treated with BAT (including ruxolitinib) who had low JAK2 allele burden or JAK2 V617F-negative disease. This data suggests that pacritinib, a JAK2/IRAK1 inhibitor, may provide benefit over a wider range of patients with myelofibrosis compared to other JAK inhibitors, specifically patients with low JAK2 allele burden who were shown to have lower baseline platelet counts, more severe anemia and smaller spleen size.

    Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies

    Results from a retrospective analysis of PERSIST-1 and PERSIST-2 will be presented in a poster session today, Monday, December 9 at 6:00 PM ET.

    Abstract: No. 4195

    Summary: This analysis was performed in patients treated on PERSIST-1 and PERSIST-2 with a baseline platelet count <50,000/μL. At 24 weeks, significantly more patients achieved ≥35% SVR with pacritinib compared with BAT (P-values <0.01). Although not statistically significant, TSS reductions ≥50% nearly doubled for those receiving pacritinib versus BAT. The safety profile in patients with severe thrombocytopenia was generally manageable and consistent with the overall study populations from the two Phase 3 trials. This retrospective analysis represents the largest population of patients with MF and severe thrombocytopenia to be studied in clinical trials, a population with a serious unmet medical need, and the results illustrate the clinical activity of pacritinib in the treatment of these patients.

    Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib

    Results from a baseline mutational analysis of patients enrolled in the Phase 2 PAC203 study of pacritinib in patients with myelofibrosis will be presented in a poster session today, December 9, 2019 at 6:00 PM ET.

    Abstract: No. 4214

    Summary: The baseline mutational analysis was performed on 105 (out of total 164 recruited, 161 treated) myelofibrosis patients in the PAC203 study. The PAC203 cohort, characterized by ruxolitinib failure and a high burden of anemia and thrombocytopenia, was shown to be a molecularly high-risk population, characterized by high incidence of HMR, TP53 and RAS mutations, high mutational burden, and low incidence of CALR mutations.

    About Myelofibrosis and Severe Thrombocytopenia

    Myelofibrosis is a type of bone marrow cancer that results in formation of fibrous scar tissue and can lead to severe anemia, weakness, fatigue and an enlarged spleen and liver. Patients with severe thrombocytopenia are estimated to make up more than one-third of patients treated for myelofibrosis, or approximately 18,000 people.1 Severe thrombocytopenia, defined as blood platelet counts of less than 50,000 per microliter, has been shown to result in overall survival rates of just 15 months.2 Thrombocytopenia in patients with myelofibrosis is associated with the underlying disease but has also been shown to correlate with treatment with ruxolitinib, which can lead to dose reductions, and as a result, may potentially reduce clinical benefit. Survival in patients who have discontinued ruxolitinib therapy is further compromised, with an average overall survival of seven to 14 months.3,4 There are currently no approved therapies available to treat myelofibrosis patients with severe thrombocytopenia, or patients who have failed ruxolitinib treatment, thereby making this a significant unmet medical need.

    About Pacritinib

    Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R. The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development, as well as inflammatory cytokine expression and immune responses. Mutations in these kinases have been shown to be directly related to the development of a variety of blood-related cancers, including myeloproliferative neoplasms, leukemia and lymphoma. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and chronic lymphocytic leukemia (CLL), due to its inhibition of c-fms, IRAK1, JAK2 and FLT3.

    About CTI BioPharma Corp.

    CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. In particular, we are focused on evaluating pacritinib for the treatment of adult patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding our expectations regarding: the anticipated trial design of the PACIFICA Phase 3 trial, including potential changes to the protocol as discussed in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019; the anticipated enrollment of the PACIFICA Phase 3 trial; the effectiveness of, and potential changes to, the PACIFICA Phase 3 trial design; the timing of, and results from, clinical trials and other development activities related to pacritinib, including the PACIFICA Phase 3 trial and its related protocol; the potential efficacy, safety profile, future development plans, addressable market, regulatory success and commercial potential of pacritinib; the anticipated timing of regulatory submissions and interactions; our ability to expedite the regulatory approval process; our ability to successfully develop and achieve milestones in the development of pacritinib; and the anticipated benefits of pacritinib.

    Risks Related to Forward-Looking Statements

    The forward-looking statements contained in this press release are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: clinical trials may not demonstrate safety and efficacy of pacritinib; the FDA may determine that the benefit/risk profile of pacritinib at the dose selected for the PACIFICA Phase 3 trial does not support approval based on the results of such trial, previously identified FDA concerns regarding safety and dosing limitations or otherwise; pacritinib may fail in development, may not receive required regulatory approvals, or may be delayed to a point where it is not commercially viable; as discussed more fully in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, if investors view negatively FDA's suggested change to the PACIFICA Phase 3 trial to include TSS as a co-primary endpoint or other potential changes to the PACIFICA Phase 3 trial that would increase the cost of the study and prolong the study, or if we are unable to expedite the regulatory approval process, we may be required to pursue strategic alternatives for the development of pacritinib and/or our company; our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations may be incorrect; we may not achieve additional milestones in our pacritinib development program; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

    "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

    CTI BioPharma Investor Contacts:
    Maeve Conneighton/Maghan Meyers
    +212-600-1902
    cti@argotpartners.com

    CTI BioPharma Corp. Logo (PRNewsFoto/Cell Therapeutics, Inc.)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-presentation-of-data-supporting-pacritinibs-benefit-in-myelofibrosis-patients-with-severe-thrombocytopenia-at-the-61st-american-society-of-hematology-meeting-300971431.html

    SOURCE CTI BioPharma Corp.

    View Full Article Hide Full Article
  53. SEATTLE, Nov. 6, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced four poster presentations and one oral presentation supporting the Company's pacritinib development program at the 61st American Society of Hematology (ASH) Annual Meeting being held December 7- 10, 2019 in Orlando, Florida.

    The details of the oral presentation are as follows:

    Abstract Title: Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib
    Session Number: 634
    Session Name: Myeloproliferative Syndromes: Clinical: JAK Inhibitors and Combination Therapies
    Session Date: Monday, December 9, 2019
    Session Time: 10:30 AM - 12:00 PM
    Presentation Time: 10:30 AM
    Publication Number: 667